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The bones in our skeleton are subjected to mechanical loading every day and are 
continuously remodelled in a process called “bone remodelling”. The capacity of the 
skeleton to adapt its mass and structure in response to mechanical loading has been 
intensively studied. Over the last few decades, much focus has been given to bone cells such 
as osteoblasts and osteoclasts but less so to osteocytes, even though these comprise almost 
90% of the cellular space in bone [1]. The detailed way these cells function in bone 
mechanotransduction and therefore control bone remodelling is not well understood. Diet 
and especially dietary fatty acids (DFA) are an important aspect of the regulation of bone 
health. Strong evidence has been presented in the scientific literature to support the 
benefits of DFA in bone health, but the exact mechanism of how they benefit bone health 
is still unclear [2-6]. 
It has been shown that bone cells secrete various osteogenic molecules in response to fluid 
shear stress. The goal of this project was to explore osteocyte cellular mechanisms involved 
in their response to mechanical loading and dietary fatty acids. This project specifically 
focused on the osteocytic secretion of ATP in response to dietary fatty acids and fluid shear 
stress in vitro. This study showed for the first time that the increased ATP secretion induced 
by fluid shear stress due to DFA treatment possibly explore a new understanding of how 
DFA might benefit bone health and could be used in future experiments to help us 
understand their possible effects. This study might be set as a model experimental design 
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Chapter 1. Introduction 
A good diet and exercise are very important to bone health and the prevention of 
osteoporosis [6-10]. The cliché "we are what we eat" appropriately defines the vital role 
food plays in overall health. The food we eat may have different fates inside the body. It 
may be catabolised to provide energy, regulate metabolism or be incorporated into 
structural elements of the body. The regulation of metabolic processes is primarily guided 
by hormones [11-13] and hormone production is altered depending on the nature of fatty 
acids (FA) present in the diet. For example, saturated and trans FAs are found to increase 
insulin resistance whereas unsaturated FAs decrease insulin resistance [14]. Similarly, 
growth hormone production is decreased when the diet is deficient of essential fatty acids 
[15]. Diets rich in omega-3 polyunsaturated fatty acids (PUFAs) from fish oil have a positive 
effect on steroid hormone production in testes of adult pigs [16]. Diets rich in omega-3 
PUFAs were found to lower coronary heart disease risk factors such as atherosclerotic and 
thrombotic factors in humans  [17]. This implies that an imbalance in such dietary fatty acid 
intake may lead to the disparity of hormone production leading to alteration of the 
metabolism. 
It is a well-known fact that exercise is good for bone health. Those who exercise have better 
bone health and structure [18-20]. In combination with other lifestyle factors, an exercise 
that starts earlier in life has been shown to contribute greatly to bone mass and health [18-
20]. Hormones such as oestrogen [21], parathyroid hormone [22], testosterone [23] and 
glucocorticoids [24], are promoted by exercise to regulate bone turnover and maintenance. 
It is believed that exercise provides mechanical stimuli to the bones and joints [25].  This 
further supported the claim, that diet and exercise have a very important role in bone 
health.  
The osteocytes are the most abundant cell type, which comprises around 90-95% of total 




matrix to the bone surfaces [1] and are in a most favourable position to detect mechanical 
stimuli [26]. These mechanical stimuli cause bone formation by releasing early mediators of 
bone formation such as nitric oxide and prostaglandins [27, 28]. These molecules are 
involved in early gene expression of c-fos and IGF-1 in osteocytes [29, 30]. Recently 
osteocytes were also found to be involved in bone mineral and phosphate homeostatic 
processes etc., as an endocrine cell [31]. These facts clearly support that osteocytes are one 
of the most important bone cells in the body for bone cell regulation. 
Mechanical loading causes the movement of the interstitial fluid in the bone to provide 
more nutrients and transporting waste products [32]. These mechanical stimuli also 
influence osteocytes to increase secretion of osteoprotective molecules such as nitric oxide 
(NO) and prostaglandin E2 (PGE2). These osteoprotective biomolecules are expressed by 
the bone cells (osteocytes and osteoblasts) in the fluid collected from osteocytic processes 
[27, 28, 33]. Where there is no movement such as in the case of microgravity [34] and 
bedridden patients [35, 36], they were found to be osteoporotic, having lower bone mineral 
density. There are different cells identified that could induce adenosine triphosphate (ATP) 
release following mechanical stress [37, 38] and the osteocytes are among them which 
release ATP in response to mechanical stress [39, 40]. Mechanical loading is sensed by 
osteocytes which secrete ATP in response. ATP and other secreted factors affect other bone 
cells to regulate bone remodelling in response to mechanical load. Osteoblastic cell lines 
such as the murine MC3T3-E1 and HOBIT cells have been shown to induce ATP release 
following mechanical stress [37, 38].  Osteoblastic activity is increased by osteocytes and 
osteoblasts when they sense the alteration in the interstitial fluid flow pressure thus 
enhancing bone formation in vivo [41-43]. These osteoblastic activities are largely driven by 
several paracrine and autocrine factors released by osteocytes and osteoblasts. ATP is an 
important signalling molecule which acts on other adjacent bone cells during 




mobilization of intracellular calcium [47, 48], regulation of gene expression [49, 50] and 
control of proliferation of osteoblastic cells [45, 51].  
Little is known about the role of dietary fatty acids on osteocyte metabolism. The studies 
so far have suggested that the dietary fatty acids have important roles in bone remodelling, 
in fact, they have been found to improve bone density and help maintain the bone structure 
[52]. The study was designed to explore the gap in the current understanding and 
knowledge about how nutrition and exercise interact to enhance or protect bone density 
at the cellular level. Dietary fatty acids might improve bone health by enhancing the 
sensitivity of osteocytes to mechanical loading and affect mechanotransduction by 
osteocytes. However, there is limited knowledge of how these dietary fatty acids influence 
osteocyte-mediated mechanotransduction.  
This project aimed to increase the basic understanding of the cellular and molecular 
processes underlying the mechanotransduction process in vitro especially in the presence 
of omega 3 and 6 fatty acids.  
Therefore, the main focus was to explore the role of the long-chain fatty acids 
docosahexaenoic acid (DHA) and arachidonic acid (AA) on osteocyte mediated 
mechanotransduction pathways that may affect the bone mineral mass. These fatty acids 
were chosen because they are two major FAs found predominantly on cell membranes. 
They are very important for neurite growth and signal transmission [53] These FA were also 
found to be good for bone health [54, 55]. These FAs supplements were shown to improve 
essential fatty acids deficiency symptoms in rodents [56]. The effect of these FAs on the 
release of ATP by MLO-Y4 cells exposed to fluid shear stress (FSS) and the result was 
analysed for any changes between different treatment groups. The MLO-Y4 osteocyte cell 
line has phenotypic similarities with primary osteocytes cells. This cell line is the selected 
cell line for assessing the function of human osteocytes. These cells exhibit identical 




osteocytes. Details about the cell line are presented in Literature review, please refer to the 
heading 2.7.4. The cells were maintained at 37°C during all the experiment processes. 
Proper care was taken to create an in vitro environment suitable for bone cells specially 
osteocyte.  
To achieve this aim, the objectives were: 
 To set up an in vitro model of osteocyte mechanotransduction in which murine MLO-
Y4 cells were subjected to fluid shear stress using the Flexcell Streamer experimental 
platform for mechanical fluid stress.  
 To use this experimental system to test the hypothesis that specific omega-3 and 6 
fatty acids found in the diet mediate their osteoprotective effect by directly 
modulating osteocyte mechanotransduction or the associated signalling pathways.  
 To perform the different tests and experiments required for method validation prior 





Chapter 2. Literature Review 
2.1. Bone: An overview 
Bone is a dynamic biological tissue, highly specialised to provide a rigid framework for the 
body. It is composed of metabolically active cells that are capable of continuous 
regeneration and repair under normal circumstances (Figure 2-1). Bones support and 
protect vital internal organs in the vertebrates. Bone stores minerals such as calcium and 
phosphorus, growth factors and cytokines and also participate in acid-base balance to 
maintain homeostasis [58]. Additionally, bone participates in haematopoiesis by housing 
bone marrow inside its internal cavities. 
 
Figure 2-1: General structure of bone, depicting gross overview and cellular distribution 




Bone maintains its balance, shape and structure in response to physical load it experiences 
as well as hormonal influences. Bone formation and resorption are continuous processes in 
healthy bones. New bone forms during embryonic growth or fracture repairs. Hormones 
such as parathyroid hormone (PTH) causes bone resorption, releasing calcium and 
phosphate into the blood circulation, whereas the hormone calcitonin promotes bone 
formation by lowering the level of calcium in the blood. Vitamin D promotes calcium 
absorption and reabsorption leading to an increase in serum calcium concentration [59]. In 
this way, these hormones function simultaneously to help in the maintenance of bone 
homeostasis. 
Recently, bone has been hailed as an endocrine organ influencing activities of various 
organs such as kidney, muscles, pancreatic cells and adipocytes [60] which affect bone 
homeostasis and health. These properties of bone made it unique and dynamic tissue. 
2.2. Bone structure 
Bone is the substance that builds the structural component of the skeleton. Structurally, all 
vertebrates possess two types of bone. More compact cortical bone and loosely arranged 
trabecular or cancellous bone (Figure 2-1). Cortical bone generally lines or covers the bone 
and it is much denser whereas trabecular bone resides in the inner part of the bone. Cortical 
bone can be found in the surfaces and shaft of the long bones while the trabecular bone is 
found in inner areas of flat bone.  
2.2.1 Cortical bone 
Around 80% of the total skeletal mass is cortical bone. This bone is comprised of highly 
organised and compact bone tissue. Cortical bone has low porosity but contains microscopic 
pores which accommodate blood vessels and nerves. Cortical bone is generally stronger and 
formed by densely packed collagen fibrils. This bone is found mostly in the periphery of long 




lamellae organization have been identified which are found in cortical bone. 1) Haversian 
systems, wherein concentric circles of lamellae surround a central longitudinal cavity 
containing blood vessels and nerves; 2) outer circumferential lamellae near the periosteum; 
3) inner-circumferential lamellae near the endosteum; and 4) interstitial lamellae, in 
between osteons and the inner or outer circumferential lamellae. 
2.2.2 Trabecular or cancellous bone 
Trabecular bone also termed cancellous bone, has a loosely organised porous matrix and 
honeycomb-like structure in the bone marrow compartment. This bone is found in ribs, 
skull, vertebrae, pelvic bones and the ends of long bones. It is generally weaker and readily 
fractured compared to cortical bone. 
2.2.3 Matrix composition 
The matrix of the bone consists of organic and inorganic components. The inorganic matrix 
of bone is primarily calcium and phosphate in the form of hydroxyapatite (Ca10(PO4)6(OH)2) 
whereas the organic matrix primarily consists of type 1 collagen, proteoglycans, growth 
factors and matrix proteins such as osteocalcin and osteopontin. 
2.2.4 The cellular components of bone  
Bone is composed of four different types of cells. Osteoblasts, osteoclasts and bone lining 
cells are present on bone surfaces, whereas, osteocytes reside deep inside in the 
mineralized matrix. The cellular components of bone can be categorized into two families. 
The first one is osteoblastic lineage which contains pre-osteoblasts, osteoblasts, osteocytes 
and bone lining cells all derived from mesenchymal stem cells whereas another being the 
osteoclastic lineage which contains osteoclasts, macrophages derived from haematopoietic 






Osteoclasts are large multinucleated cells originating from myeloid hematopoietic stem 
cells. These cells are generally formed by the fusion of monocyte progenitors. These cells 
resorb bone during the bone remodelling and turnover process. Osteoclasts have a special 
type of plasma membrane which is highly folded and participate in the bone resorption site 
by latching onto the bone surface and sealed by integrin [62].  
Osteoclasts are activated by Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL; 
which binds to RANK receptors on its surface) and macrophage colony-stimulating factor 
(M-CSF) released from osteoblasts and osteocytes. These factors support the osteoclast to 
mature, differentiate and progress toward the bone resorption activity. Osteoclasts secrete 
acid phosphatase which can be used as an identifier or marker. Osteoclasts secrete 
hydrochloric acid which breaks down bone and then secrete metalloproteases which will 
dissolve the collagen [63]. Osteoclasts derive H+ from the proton pump and Cl- from the 
inner cell membrane of the ruffled border [64]. They resorb the bone at Howship lacunae 
where osteoclasts secrete tartrate-resistant acid phosphatase and cathepsin K [63, 65]. This 
will degrade the bone by lowering the pH and digesting the organic matrix. 
Osteopetrosis, Paget’s disease and Gorham-stout syndrome are some clinical conditions 
that arise due to osteoclast dysfunction [66]. These clinical conditions are the result of 
altered bone vasculature supply where the osteoclasts have a compromised role and cannot 
perform their normal activity. 
2.2.4.2. Osteoblasts 
Osteoblasts are cuboidal cells that are derived from undifferentiated mesenchymal cells. 
Osteoblasts secrete osteoid to produce bone matrix [67]. The major function of the 
osteoblast is the secretion of type 1 collagen. Osteoblasts control the formation of the bone 




from 20-30 micrometres in diameter. Alkaline phosphatase which acts as osteoblast marker 
is found mostly in the cytoplasm and nucleus of this cell. They have parathyroid hormone 
receptors on their cell surface which signal osteoblasts to secrete RANKL. RANKL influences 
osteoclasts by binding to its receptor RANK and promoting differentiation and activation of 
osteoclasts. Osteoblasts also have receptors for oestrogen and vitamin D on their surface 
which suppresses osteoclastic functions and support bone formation. 
2.2.4.3. Osteocytes 
Osteocytes are stellate shaped mature osteoblasts which reside deep inside the bone 
matrix. They are formed when the ageing osteoblasts are trapped inside the bone matrix 
during ongoing bone formation. These are the most prevalent cell type in bone. Their 
shapes vary with the location in which they reside. Cells within trabecular bone have a 
rounded shape whereas the cells from cortical bone have an elongated form [68]. They are 
the most numerous type of bone cells occupying around 90-95% of the total cellular space 
[69, 70]. Osteocytes are connected to other osteocytes and bone cells through fusion of gap 
junction proteins of the dendritic processes within the lacuno-canalicular network to 
communicate with each other. These cells used to be regarded as inactive and dormant but 
are active and dynamic. Osteocytes can synthesize collagen, control bone mineralization 
within their lacunae and can carry out lacunar demineralization surrounding them 
(osteocytes). When osteocytes were exposed to PTH, these peri-lacunar demineralizations 
were found to be more prominent, which was recovered by the administration of calcitonin 
[71, 72].  
2.2.4.4. Bone lining cells 
Bone lining cells are flat and elongated cells found mostly on the bone surfaces. It had been 
speculated that bone lining cells were precursors of osteoblasts. These are generally 




collagenous material by secretion of the metalloproteinase from the bone surfaces. After 
clearing the surfaces, they smooth the layer by secreting collagen on top of it [73-75]. 
2.3. Regulation of Bone Homeostasis 
Calcium and phosphate ions are so important in bone health that their homeostasis is 
maintained by two different mechanisms. These are hormonal (endocrine) and non-
hormonal (local) mediators. 
2.3.1 Endocrine regulation 
Calcium and phosphate level regulation in the blood is a prerequisite condition for normal 
bone homeostasis. Calcium and phosphate concentration in the human body is controlled 
by three different types of hormones. These are parathyroid hormone (PTH), calcitonin and 
vit D3 (1, 25-OH vitamin D3). These hormones act on kidney, bone and the gastrointestinal 
tract (GIT) to regulate bone homeostasis. 
2.3.1.1. Parathyroid hormone  
Parathyroid hormone (PTH) is the most important hormone that regulates calcium and 
phosphate levels in the blood. It is an 84 amino acid polypeptide produced by the chief cells 
of the parathyroid gland. There are four parathyroid glands, two on each side of the dorsal 
surface of the thyroid gland. PTH increases calcium release from the bone by enhancing 
reabsorption of calcium from the distal nephron by ATP dependent and sodium gradient 
dependent mechanisms [76] and reducing the reabsorption of phosphate from kidney, 
resulting in phosphate excretion through the urine, usually resulting in bone loss [77].  
Another factor controlling and lowering PTH secretion is a high concentration of 1, 25-
dihydroxy vitamin D [78]. It increases circulating Ca2+ which activate the calcium-sensing 
receptor (CaSR) located at the chief cells, which gives negative feedback and decreases PTH 




of PTH secretion from chief cells. A study by Jono S et al showed that 1,25 vit D suppresses 
the PTH related peptide expression in bovine vascular smooth muscle cells (BVMC) and 
promote calcification [80]. The overall outcome of the 1,25 vit D effect is the suppression 
of PTH synthesis by the parathyroid cells [81, 82]. 
PTH’s net effect in bone is an increase in bone resorption by activating osteoclasts. 
Osteoblasts respond to PTH by producing IL-1, IL-6 and other cytokines which trigger 
osteoclastic differentiation [83-86]. PTH also influences osteoblasts to produce more RANKL 
[87] and M-CSF [88] that induce differentiation and proliferation of osteoclasts. Another 
study suggests that PTH induced osteoblasts secrete monocyte chemoattractant protein 1 
(MCP-1) which enhances the fusion of and multinucleation of pre-osteoclasts [88]. 
2.3.1.2. Calcitonin  
Calcitonin sometimes referred to as thyrocalcitonin, is a 32 amino acid containing 
polypeptide hormone produced by the C-cells in the thyroid gland. Calcitonin increases the 
calcium excretion in urine, lowering the calcium and phosphate level in the blood. Calcitonin 
deficiency is associated with higher bone mass in mice suggested it to be a bone formation 
controller in the skeletal system [89-91].  
2.3.1.3. Vitamin D3  
The two major types of vitamin D are vit D2 or ergocalciferol and vit D3 or cholecalciferol. 
Cholecalciferol or vit D3 is an active form. Vit D3 can be taken in the diet, mainly from dairy 
products, fish and oils or synthesised in the body in the presence of sunlight. When 
ultraviolet rays hit the skin from the sun, vit D3 is produced. The precursor to vit D3 found 
in the skin is termed as 7-dehydrocholesterol. This 7-dehydrocholesterol is converted to 
cholecalciferol in the presence of ultraviolet light at the wavelength of 290-315nm. This 
cholecalciferol is transported by vitamin D binding protein (DBP) to the liver where it is 




reticulum in the presence of magnesium by the enzyme 25 hydroxylase a member of 
cytochrome p450. After this, 25 hydroxy Vit D3 again enters the circulation and is 
transported to the kidney by DBP. When reaching the kidneys this 25 hydroxyvitamin D3 is 
converted to 1, 25 hydroxyvitamin D3 or simply 1, 25 vitamin D3 which is an active form of 
vitamin D3. This process occurs in mitochondria of the renal proximal convoluted tubule in 
the presence of at least three enzymes called renal ferredoxin reductase, renal ferredoxin 
and cytochrome P450. 
PTH also increases the serum calcium concentration by affecting the osteocytic osteolysis, 
pattern seen in the lacunae of the osteocyte and was first described morphological by Baud 
[71]. These lacunae where osteocytes reside were found to be enlarged with the continuous 
administration of PTH [92]. These resorptions of lacunae were found to be decreased with 
the administration of calcitonin [93, 94]. 
2.3.2 Local regulation 
When the body recognises the low amount of calcium and phosphate ions in the blood 
plasma, a homeostatic mechanism allows these ions to move out from the hydroxyapatite 
crystal where they were situated and stored within the bones into the extracellular fluid. So 
this non-hormonal response is usually quick. Generally local regulation aids the hormonal 
regulation as it solely cannot fulfil the greater demand of the body. 
The table below summarises the role of PTH, vit D3 and calcitonin in the various parts of the 






Table 1: Hormones involved in calcium and phosphate homeostasis 
 PTH Vitamin D3 Calcitonin 
Kidney Increase the activity of 1α 
hydroxylase to promote vit 
D3 synthesis 
Increase reabsorption of 
calcium in the distal tubule 
Decrease phosphate 
















concentration but increase 
calcium concentration in 
plasma. 
 
Increase calcium and 
phosphate 
concentration in the 
plasma. 




Bone Increase the maturation of 
osteoclast and osteoclastic 
activity.  
A decrease in osteoblast 
collagen in the matrix. 
 
Stimulates PTH which 
then increase calcium 
reabsorption only and 
decrease phosphate 







concentration but increase 






















Increases calcium and 
phosphate concentration in 
plasma 
Increase calcium and 
phosphate 







2.4. The Wnt signalling pathway in bone turnover 
The purpose of this signalling pathway is to regulate cell proliferation, maturation, 
differentiation by initiating cellular and nuclear processes (Figure 2-2). Wnt signalling 
stimulates mesenchymal stem cells (MSC) to differentiation into osteoblast lineage cells 
rather than differentiating into adipocyte lineage cells, which supports bone formation [95]. 
Osteocytes sense and adapt to a different mechanical stimulus by the help of the wnt 
signalling pathway [96].  
When wnt is available, β-catenin is not destroyed and proceed towards the nucleus and 
start gene activation. Canonical Wnt signalling mediates its effect by binding Wnt proteins 
to a receptor complex that includes a member of the frizzled family of seven 
transmembrane receptors and either LRP5 or LRP6 [97]. Wnt molecules bind with the 
receptor in the frizzled (Fz) and co-receptor LRP5/6, this activates the wnt receptor 
complex. Binding of wnt to receptor complex leads Dishevelled (DSH) to relocate to the 
membrane and Glycogen synthase Kinase (GSK3β) to displace from the destruction complex 
which generally consists of Glycogen Synthase Kinase 3β (GSK3β), the scaffold protein Axin, 
the tumour suppressor Adenomatous Polyposis Coli (APC), protein phosphatase 2A and 
casein kinase 1α (CK1α). The mechanism of displacement of GSK3β from the destruction 
complex by the action of wnt receptor complex is unclear. This binding of wnt to the 
receptor complex also causes Axin and destruction complex to relocate to the plasma 
membrane. Axin binds to LRP5/6 which is phosphorylated by GSK3β and CK1α. By already 
phosphorylating the LRP 5/6 receptor, GSK3β and CK1α cannot phosphorylate the β-catenin 
and therefore cannot signal it to ubiquitination and proteasomal degradation.  Because of 
no destruction of β-catenin, the level of it increases and it enters the nucleus. It binds there 
with LEF/TCF family of transcription factors to initiate transcription of targeted genes. 
When there is no wnt molecule present, the GSK3β and possibly CK1α phosphorylates the 




phosphorylation of β-catenin marks it for degradation and proceeds towards the 
destruction. 
DKK1 and sclerostin block wnt molecules and prevent wnt from binding with LRP receptor 
molecules. These antagonists combine with LRP molecules and occupy the LRP receptor 
where wnt binds. GSK3β phosphorylates the β-catenin and send it for the proteasomal 




Figure 2-2: Wnt signalling pathway in osteoblasts.  
Without wnt activation (off state), beta-catenin is tagged by destruction complex for 
proteasomal degradation. With wnt activation (on state), binding of wnt and 
receptor complex destroys the destruction complex which leaves beta-catenin in the 
cytosol. Then beta-catenin will enter the nucleus and start the expression of target 





Wnt/β catenin signalling is very important to the bone development and regulation of bone 
mass. Wnt signalling in bone leads to osteoblast differentiation, proliferation, function and 
survival and hence increased bone mass [99]. Studies have revealed that mutations in LRP5 
lower the bone mineral density implying the important role of LRP5 in mechanical signalling 
[100, 101]. The mechanism underlying the effect of LRP5 mutations on bone mass is yet 
unclear. Sclerosteosis and van Buchem disease [102, 103] are some of the bone disorders 
associated with an impaired SOST gene which encodes for sclerostin. These diseases are 
associated with thicker and denser bone mass affecting mostly the skull, jaw and long bones 
[104]. 
2.5. Role of different bone cells in bone remodelling 
Bone remodelling is a process in which continuous removal of old bone and formation of 
new bone simultaneously occurs in the skeleton. Bone remodelling takes place within the 
Basic multicellular unit (BMU), where these bone cells participate simultaneously in the 
bone formation and resorption process. The bone remodelling process ensures proper bone 
structure, properties and characteristics of bone. Osteoblasts, osteoclasts and osteocytes 
are the key participants of the bone remodelling process.  
Osteocytes: The osteocytes comprise around 90-95% of the total cellular space. They are 
also interconnected with other bone cells such as osteoblasts, osteoclasts and other 
osteocytes with a dendritic structure that allows cell communication and viability [105]. 
Osteocytes regulate osteoblasts and osteoclasts during bone remodelling process to ensure 
stable bone structure [106, 107] and because of this, the osteocytes are called the “master 
orchestrators of bone’’ [108]. Osteocytes can regulate osteoblasts and osteoclasts either by 
promoting or inhibiting their activity. Osteocytes control the osteoclasts by stimulating or 
promoting their differentiation by providing signalling molecules, RANKL [109-111] and M-




resorption. They have found that the RANKL produced by osteocytes is responsible for 
osteoclastogenesis [111]. Osteocytes secrete PGE2, NO and ATP, which stimulates 
osteoblastic activity and inhibits the maturation of osteoclasts [112-114]. Transforming 
growth factor β-1 (TGFβ-1) released by osteocytes and the bone matrix inhibits osteoclastic 
activity and prevent bone resorption whereas it also stimulates osteoblasts to recruit at the 
site of bone resorption to form new bone [113, 115]. At these sites, osteoblast and 
osteocytes also secrete osteoprotegerin (OPG) which inhibits osteoclast differentiation. 
OPG acts as a decoy receptor by binding with RANKL thereby preventing RANKL to interact 
with RANK on the osteoclasts [107].  
Mature osteocytes secrete a signalling molecule called Sclerostin encoded by the SOST 
gene, which is a significant regulator to inhibit bone formation [116]. Sclerostin binds with 
the low-density lipoprotein (LDL) receptor-related protein 5 (LRP5) and prevents it from 
binding with Wnt molecules [117]. This sclerostin and LRP5 binding negatively regulates the 
canonical Wnt signalling pathway in osteoblasts and inhibits osteoblast activation [118, 119] 
and bone formation. Mechanical loading supports bone formation by decreasing the 
expression of sclerostin in osteocytes [120]. The excessive bone formation may arise due to 
disorders of sclerostin synthesis in osteocytes or from the mutation of LRP5 [121, 122]. By 
this process, osteocytes act as a mediator and regulate the osteoclast and osteoblast 
activity during the bone remodelling process [123, 124].  
Apart from controlling the function of osteoblasts, osteocytes can undergo de-
differentiation back to osteoblasts. This was found to be occurring during the healing of 
injuries which require migration and proliferation of osteoblasts. The exact mechanism by 
which osteocytes sense these signals to de-differentiate back to osteoblasts is not yet clear 
and more study in this area is required [125, 126]. 
The osteocyte also releases soluble factors that regulate phosphate homeostasis. The 




inorganic phosphate which will ultimately decrease the bone mineralization. However, 
when dentin matrix protein-1 (DMP1) and phosphate-regulating gene with homologies to 
endo-peptidases on the X chromosome (PHEX) are expressed, FGF23 [127] expression is 
decreased leading to high renal absorption of phosphate, allowing mineralization of the 
bone matrix.  
Osteoclasts: Osteoclasts usually accumulate by chemotaxis in resorption space1. These 
resorption spaces are also called Howship’s lacunae where bone resorption occurs.  
Osteoclasts clear and resorb the bone, which creates spaces for osteoblasts to form bones 
in the Howship’s lacunae. The osteoclasts form an extensively folded structure called the 
ruffled border which increases the surface area to cover the bone pit to facilitate bone 
resorption (Figure 2-3). After settling onto the surface of the bone, osteoclasts release 
several enzymes such as acid phosphatase, tartrate-resistant acid phosphatase and 
cathepsin K, which breakdown bone into calcium and phosphorus ions which causes a 
breakdown of bone or bone resorption.  
Osteoblasts: After osteoclastic bone resorption, the osteoblast takes the lead by secreting 
type 1 collagen and mineralizes the area to build bones on top of it [128, 129]. Like 
osteocytes, it also secretes RANKL [130] which helps osteoclasts to proliferate and 
differentiate. Osteoblasts primarily lay down new bones during remodelling and skeletal 
development process [131]. 
                                                        
1 It is the space where osteoclasts remove bone. Osteoblast need resorption spaces to 





Figure 2-3: Interaction of bone cells: osteocytes, osteoblasts and osteoclasts during 
bone remodelling.  
Osteocytes secrete M-CSF and RANKL to support osteoclast differentiation and 
maturation. Osteocytes also secrete OPG, NO and TGFβ inhibit the osteoclastic 
activity and support osteoblastic activity. It also secretes sclerostin and DKK1 to 
inhibit bone formation (adapted from [31, 132]). 
2.6. Osteocytes: Response to nutrition and exercise 
Physical activity and good nutrition contribute significantly to the prevention of 
osteoporosis, a significant problem in an ageing population [7-10, 133, 134]. The positive 
effect of diets supplemented with omega fatty acids and regular exercise on improving bone 
density in the young and old people is well known [7-10, 133-136]. 
Bone turnover is influenced strongly by the nutritional status of the individual [133]. Recent 
studies show that the incidence of osteopenia and osteoporosis was improved by dietary 
supplementation of omega-3 fatty acids (FA), although the exact mechanism is not 




also been found to inhibit bone loss by lowering RANKL production in the stromal cells [137]. 
Deficiency in dietary omega-3 FA is linked with decreased bone density [2]. A 
Mediterranean diet, rich in olive oil and oleic acid results in a lower incidence of bone 
fractures and correlates with higher bone mass [138, 139] whilst a ketogenic diet (high fat, 
fewer carbohydrates) lowers the bone mass [140]. Omega-3 and omega-6 FA are shown to 
have a beneficial effect on bone health [5] with a lower fracture rate [141], and a higher 
bone mineral density [142] in various studies. 
Mechanical loading and exercise positively affect bone remodelling. It was demonstrated 
that mechanical loading increases osteocytes viability [143] and that physiological fluid 
shear stress is important in osteocyte survival [144]. Osteocyte apoptosis was linked to 
experimental mice and rats having low [145, 146] and or excessive [147, 148] mechanical 
loading. Local skeletal micro injuries resulting from a bone fracture can also lead to 
osteocyte necrosis or apoptosis. Necrosis and apoptosis of osteocytes promote osteoclast 
bone resorption [108, 149]. To show this, Cardoso et al [150] completely inhibited the 
resorptive activity of osteoclasts by blocking osteocyte apoptosis They have used pan-
caspase inhibitor Q‐VD‐OPh (quinolyl‐valyl‐O‐methylaspartyl‐[‐2,6‐difluorophenoxy]‐
methylketone to inhibit the osteocyte apoptosis. They have found that apoptosis inhibition 
has suppressed the intracortical resorption. This study further supports the work of Tatsumi 
et al [151], in which they have shown that gene-targeted ablation of osteocytes causes rapid 
bone loss. These studies firmly support the idea of osteocytes regulating osteoclasts in the 
bone turnover process.  
At zero gravity and in microgravity environments, astronauts experience a higher loss of 
bone mineral density [152-154]. This bone loss is associated with higher bone resorption 
and lower calcium absorption [155] due to decreased loading in zero gravity. Bone mass 
significantly increases after the space flight (post-flight) due to reloading of the bone which 




bone resorption [155]. In other studies, exercise such as strength training, resistance 
training had reduced bone loss in elderly and postmenopausal women [156-159]. Similar 
results were obtained in a study where mice had shown improved bone and structure in the 
region where mechanical loading was applied, possibly due to enduring the applied stresses 
[160, 161]. These reports suggest that the absence of loading decreases bone mass and vice 
versa. Tatsumi et al [151] also prevented the unloading induced bone loss by selective 
ablation of 70-80% of the osteocytes in mice. They showed that osteocytes can sense 
mechanical unloading and induce subsequent bone resorption. 
Mechanical unloading has been reported to induce osteocytes hypoxia in vivo [162]. The 
metabolic needs and nutrient demands of the deeply embedded osteocytes are met when 
forces generated by mechanical loading and fluid shear stress [163] act on them. It is shown 
that the disuse of bone leads to the diminished nutrient supply to the deeply embedded 
osteocytes through the vasculature. This disuse induced hypoxia upregulates the hypoxia-
inducible transcription factor (HIF-1α) and osteopontin in osteocytes [162, 164]. Since the 
hypoxia-induced osteocyte expression of osteopontin has been suggested to induce 
osteoclast chemotaxis and adhesion [165], it can be speculated that mechanical unloading 
plays a crucial part in osteoclastic bone resorption although the actual mechanism is not 




2.7. Mechanical loading and bone 
2.7.1 History 
For a long time, people have been fascinated by the fact that lifestyle, diet and environment 
affect bone structures. In ancient literature, Greeks and Italians have mentioned the effect 
of different lifestyles on skeletal mass. In 1638, Galileo first indicated that the shape of 
bones is determined by the load they bear, but the scientific study started only at the 
beginning of the 19th century [166]. In 1867, Von Meyer noticed the distorted trabecular 
arrangement in the sagittal section of bone which Karl Culmann claimed as Culmann’s 
‘crane’, these are results of the load they bear [167]. At the beginning of 1869, Julius Wolff 
suggested a novel Wolff’s law [168],  which states that the structure of bone is the result of 
the loading and direction of the load it faced or carried [169]. He described bone as an organ 
capable of producing new bone or removing bone. He suggested that the area of increased 
loading builds new bone and regions of decreased loading removes bone. This law was 
subsequently developed by Roux as the idea of functional adaptation in bone [170]. Harold 
Frost [171] has explained in his popular mechanostat hypothesis that the loading is the 
controlling factor which determines the bone structure and shape. 
2.7.2 Mechanical loading and role of osteocytes 
Mechanical loading affects bone development and differentiation. Mechanical loading 
increases bone mass [172, 173] and unloading or immobilisation of the bone leads to a loss 
in the bone mass [174, 175]. The bone cells which can sense this loading include osteoblasts 
and osteocytes. 
The osteocyte is the most sensitive cell that can experience shear stress compared to 
osteoblasts or fibroblasts [26] and it also comprises 90-95% of the total cellular mass in 
bone [176]. Due to their sheer number and interconnectivity, osteocytes are likely the major 




to cause osteocyte apoptosis in vivo [145], which ultimately leads to a reduction in its 
mechanosensory activity in bone.  
Osteocytes communicate with other bone cells by two types of mechanisms. One 
mechanism is a diffusion of molecules about 1 kDa through gap junctions (connexin 43 is 
the most common gap junction protein in the osteocyte). Another mechanism allows 
communication through paracrine signalling in which molecules such as prostaglandins 
(PG), Adenosine triphosphate (ATP), Fibroblast growth factor 23 (FGF23) and RANKL are 
secreted by osteocytes and transported to other bone cells [7]. The dendrites can reach to 
the bone marrow and interconnect with other marrow cells [178] which indicates that 
osteocytes have far greater range compared to the other bone cells.  
The most potent mechanical stimulus that the osteocytes respond to is interstitial fluid flow. 
The mechanical stimulus is primarily received by the body in the form of muscle contraction. 
First, muscle contraction leads to bone deformation. These mechanical load experienced by 
the bone is directly proportional to the mass of muscle that is contracting. Mechanical 
loading causes compression of the calcified matrix and the region of lacuna-canalicular 
space which house osteocytes and their dendritic processes [179-181]. This extravascular 
pressure drives the extracellular fluid to low-pressure regions [182]. The exact mechanism 
by which osteocytes sense the mechanical loading is still unclear, but it is believed that the 
osteocytes experience shear stress because of fluid flow pressure that distorts these cells 
and dendrites within the lacunar canalicular system. Three different hypotheses are 
suggested based on three different parts of the osteocytes. These are responsible for 
processing mechanical stimuli into the biochemical signals that regulate various 
downstream signalling pathways. 
The effect of loading on bone cells varies greatly depending on the location at which these 
cells exist [183]. These cells experience fluid shear stress in the interstitial fluid ranging from 




Osteocytes evolved from the mature osteoblast entrapped inside the osteoid matrix [184], 
but they are also more sensitive than the osteoblast precursor, responding profoundly to 
shear forces in the interstitial fluid compartment [185]. Osteocytes sense mechanical 
stimuli received from mechanical loading using three different anatomical features of the 
cells. After receiving mechanical signals, osteocytes convert them into biochemical 
messages directing the differentiation and recruitment of osteoblasts and osteoclasts. The 
exact mechanism by which osteocytes sense different stimuli and secrete or express 
different types of molecules remains unclear. It is believed that they may sense through 
deformation of the cell body [186], through dendritic processes (dendrites) [187] or bending 
of specific solitary ciliary extensions [177].  
 Integrins: It has been found that there are some extensions from the cytoskeleton 
to the extracellular matrix that sense the signal from fluid shear stress. The cell extensions 
then amplify this signal from FSS, ten times inside the cell [188]. Later these cell extensions 
were confirmed as Integrins [189]. It is thought that fluid flow stress induces 
mechanosensation in osteocytes through perturbation of integrins which when excited by 
shear stress, open hemichannel (connexion 43 (CX43) in osteocytes) to release 
prostaglandin E2 [190-192]. It is postulated that Integrins are mechanosensors responsible 
for converting the mechanical signal into a cellular response [193, 194]. Integrins are major 
receptors and transducers that help in communication with the outside of cells and various 
cell membrane-bound proteins. Studies [195, 196] indirectly support the idea that integrin 
conformation is modulated by applied force. 
 Cell body: Fluid shear stress is experienced by the cell processes and cell body 
similarly [197] but Anderson et al [198] refuted this by presenting a finite element model of 
the osteocyte. He showed that while shear stress exists on the cell process, the cell body is 




process joins the cell body. However, it is not known yet, whether the cell body or the cell 
process is stimulated in vivo that results in mechanotransduction. 
 Cilium: Cells extend a non-motile primary cilium that protrudes from the cell surface. 
Cilium has been proposed to work as signal receivers and sensors [199], by acting as a 
mechanosensory organelle [200]. Bending of this cilium by the response to fluid shear stress 
has been shown to increase intracellular calcium level [201] however it is also shown to 
work individually in bone cells [202]. Malone et al. demonstrated that the cilia in osteoblasts 
and osteocytes are required for responses to dynamic fluid flow independently from Ca2+  
influx [202]. Mutation in the cilia-related gene, Pkd1 displayed a defect in bone 
development and decreased runx2 expression in mice [203].  
2.7.3 Osteocyte in bone mechanotransduction 
Converting mechanical signals into cellular biochemical reactions in a series of signalling 
pathways is called mechanotransduction. The osteocytes respond to these mechanical 
signals by releasing signalling molecules which will control the activity of osteoblasts and 
osteoclasts in the bone. Due to their sheer number, interconnection and location they are 
considered a major player in mechanotransduction.  
Mechanical loading is a controlling factor responsible for the molecular and physical 
adaptation of bone. Short term loading induces (seconds to minutes) ATP secretion, 
increases intracellular calcium whereas long term loading (minutes to an hour) causes the 
secretion of NO and PG [204, 205] in osteocytes and osteoblasts. There are numerous 
factors secreted by osteocytes in response to mechanotransduction. These are 
 ATP: Chloride-conducting channels [206, 207], gap junctional hemichannels [37, 
208], and vesicular transport [209, 210] are suggested for the mechanism of secretion of 




 PG: The release of prostaglandins (PG) is essential for cell proliferation, 
differentiation and survival.  
 NO: Nitric oxide (NO) has a different action in different systems as such in the 
neuronal system, in blood pressure control, during inflammation and bone mass regulation 
[211-215]. 
2.7.4 MLO-Y4 cells as a model for osteocytes 
The murine long bone osteocyte Y4 (MLO-Y4) cell line has been selected for our 
experimental work. This cell line is the selected cell line for assessing the function of human 
osteocytes. MLO-Y4 cells exhibit identical characteristics of osteocytes in vivo in terms of 
secretion of various markers specific to osteocytes. MLO-Y4 cells express a low amount of 
alkaline phosphatase (ALP) activity but a high secretion of osteocalcin. Similarly, this cell 
line shows high expression of connexion 43 (CX43), a type of gap junction protein and the 
antigen E11 [216]. This cell line also possesses dendrites which are identical to osteocytes 
[217].  These cells secrete a very low amount of sclerostin, compared to osteocytes [218]. 
It has been confirmed that these cells are highly sensitive and useful for studying the release 
of signalling molecules such as ATP, NO, PGE2 and calcium in response to fluid flow 
experiments [184, 219]. These cells are used in our fluid shear stress experiments detailed 





2.8. Fatty acid overview 
Fatty acids (FA) are the simplest form of lipids. These are a long chain of hydrocarbon with 
a carboxylic acid at the terminal end. Glycerol or other compounds serves as a backbone 
structure and incorporate fatty acid in it. There is rarely a fatty acid found in a free state. 
Most naturally occurring fatty acids except in marine animals are even numbers of carbon 
atoms because the synthesis of fatty acids occurs in a sequential addition of two-carbon 
units.  
Fatty acids can be classified into saturated and unsaturated based on the double bonds it 
contains in their carbon chain. If all the carbon bonds are single, then the fatty acid is termed 
as saturated and if it contains one or more double bonds then it is called an unsaturated 
fatty acid. Unsaturated fatty acids are more prevalent in plants compared to saturated fatty 
acid. The saturated fatty acid can pack closely to form a rigid structure but unsaturated fatty 
acids prevent such close structure and tend to be more fluidic and random. 
The unsaturated fatty acids can be further divided into omega-3 and omega-6 fatty acids. 
First double bond occurring to carbon unit number is counted from the methyl end to 
determine the nature of unsaturated fatty acid. In omega-3 fatty acid double bond starts at 
the number three-carbon units, whereas if the double bond starts at carbon number 6, then 
the fatty acid is termed as an omega-6 fatty acid. Linoleic acid (LA; 18:2n-6) and arachidonic 
acid (AA; 20:4n-6) are the examples of omega-6 fatty acids whereas α-Linolenic acid (ALA; 
18:3n-3), stearidonic acid (SDA; 18:4n-3), Docosapentaenoic acid (DPA; 22:5n-3), 
Docosahexaenoic acid (DHA; 22:6n-3) and Eicosapentaenoic acid (EPA; 20:5n-3) are 
examples of omega-3 fatty acids. Omega-3 FA is found mostly in oily fish and green leafy 





2.9. Fatty acid metabolism 
General fatty acid (FA) oxidation and synthesis are both metabolic processes of FA but 
reaction steps are reverse to each other.  
In FA oxidation, long-chain aliphatic carbon chains are broken down into activated acetyl 
CoA which is utilised in the Krebs cycle. Whereas in synthesis, monomeric activated acyl 
CoA (acetyl CoA) and Malonyl CoA condense to form long-chain aliphatic carbon 
compounds in a series of steps. The formation of Malonyl CoA is the prerequisite step or 
rate-limiting step in the fatty acid synthesis. Fatty acids are synthesized in the cytosol, while 
fatty acids are broken down in the mitochondrial matrix. Fatty acids are synthesized by the 
repetition of condensation, reduction, dehydration and reduction reaction sequences. The 
reductant in FA synthesis is NADPH, but the oxidant in FA degradation are NAD+ and FAD. 
2.10. Metabolism of omega-3 and 6 fatty acids 
Lipid is taken in the form of triacylglycerols [220] in larger amount whereas cholesterols, 
phospholipids etc. are taken in a smaller amount in the diet. Fatty acids which are essential 
to vertebrates, cannot be synthesised inside the body so needed to be provided in the diet 
are called essential fatty acids [221]. Humans cannot produce alpha-linolenic acid (ALA) or 
linoleic acid (LA) which are the precursor molecules for the omega-3 and omega-6 fatty 
acids respectively because the body cannot insert double bonds beyond carbon number 9 
[222]. Vegetable oils and egg yolk are a good source of linoleic acid whereas linolenic acids 
are found in oils, fish and liver.  
The desaturation and elongation reactions occur in both omega-6 FA and omega-3 FA 
families (Figure 2-4). The LA and ALA have an opposing function and generally compete for 
the same enzyme involved in the elongation desaturation process [223-225]. LA and ALA 
act as the precursors which convert to various eicosanoids and docosanoids through 






Figure 2-4: Metabolic pathway of the omega 3 and omega 6 




2.11. Effect of dietary fatty acids on bone health and diseases 
Dietary intake of omega-3 and omega-6 FA has proved to be a crucial factor in promoting 
good bone health in animals and humans. A diet rich in omega-3 FA leads to greater bone 
density and mineral content in free-range laying hens [54] and young piglets were found to 
have improved bone mineral density when fed with a diet rich in omega-6 FA [55]. Improved 
supplementation of omega-3 FA decreases N-telopeptides (NTx) which is a bone turnover 
marker which indicates bone loss in humans [228]. Omega-3 and 6 FA supplementation are 
found to have a beneficial effect in bone mineral density of postmenopausal women [229-
232].  Omega-6 fatty acid together with omega-3 fatty acids show a protective effect on 
bone in postmenopausal women compared to the placebo group [233]. However an 
increased ratio of omega-6/omega-3 food intake is shown to increase PGE2 [234, 235], 
lower BMD [236], possibly due to the modulation of mesenchymal cells towards 
adipogenesis inhibiting osteoblastogenesis [237].  
Long-chain polyunsaturated fatty acids are very important lipid components in all tissue 
membranes. They are responsible for the membrane fluidity, flexibility and permeability, 
which will allow transportation of various molecules [238]. Anomalies in the fatty acid 
constituents of the cell membrane are found to cause decreased membrane fluidity in NP-
C fibroblasts cells [239]. Irregular metabolism of EFAs has been associated with diseases 
such as cystic fibrosis [240], Crohn’s disease [241], acrodermatitis enteropathica [242], 
Sjogren syndrome [243], cirrhosis and Reyes syndrome. There is evidence that omega -6 
fatty acids such as linoleic acid, gamma-linoleic acid and arachidonic acid enhance cancer 
and metastasis [244] whereas DHA and EPA are shown to inhibit the growth of tumours and 





2.12. The effects of DHA and AA on bone cells 
Maurin et al [247] studied the effect of dietary fatty acids, DHA and AA on human primary 
osteoblastic cells. They showed that these fatty acids inhibit osteoblastic proliferation 
through cell cycle arrest in the G1 phase. They further discovered that these FAs directly 
activate PPARy and disturb osteoblast function in age-related bone loss patients [248]. 
Coetzee et al [249] studied the effect of AA and DHA on osteoblastic cell lineage MG63 and 
MC3T3-E1 and found a similar trend, that these fatty acids inhibited the proliferation of 
MG63 and MC3T3-E1 cells. Kruger et al [2] suggested that omega-3 FA improves bone mass 
by increasing the number of mesenchymal stem cells and committing them towards 
osteoblasts formation. Omega-3 FA also inhibits osteoclastogenesis by downregulation of 
Nuclear Factor-KappaB-Inducible Nitric Oxide Synthases (NF-κB-iNOS) signalling [250], 
suppressing TNFα [251] and RANKL signalling [252] whereas omega-6 improves bone mass 
by inhibiting inflammatory cytokines [253]. 
Nakanishi et al [254] claimed in their studies that dietary omega 3 fatty acids cause 
suppression of TNF, NFkB, MCSF and RANKL which inhibit the function of the osteoclasts 
and prevent excessive bone resorption. Similarly, Boeyens [255] has shown that AA and 
DHA are both effective in the inhibition of RANKL induced osteoclast formation in 
RAW264.7 cells with DHA having the strongest inhibitory effect. They claimed that these 
polyunsaturated fatty acids can be important in controlling bone loss resulting from 
hyperactivity of osteoclasts. Another study by Kasonga et al [256] showed that AA and DHA 
inhibit various osteoclastogenic markers such as CTSK, TRAP and MMP-9 affecting 
osteoclast differentiation and activity. In a study by Casado-Diaz indicated that the omega 
6 AA fatty acid favours mesenchymal cells to commit towards adipogenesis more readily 
than omega-3 EPA and DHA fatty acid. This adipogenic activity of AA is independent and the 




Chapter 3. Materials and methods 
3.1. Reagents 
Minimum Essential medium α (α-MEM) containing sodium pyruvate, Phenol red & L-
glutamine (Gibco Cat# 12571-063), Collagen I rat protein (3 mg/ml; Gibco Cat# A1048301), 
heat-inactivated Fetal Bovine Serum (FBS; Gibco Cat# 10082-147), Penicillin-Streptomycin 
(10,000 U/ml; Gibco Cat# 15140-122), and Trypsin EDTA (0.05%; Gibco Cat# 25300-054) 
were all purchased from Thermo Fisher Scientific, Auckland, New Zealand. Iron-enriched 
bovine calf serum (CS; Hyclone Cat# SH30072) was purchased from Invitro Technologies, 
Auckland, New Zealand. 
An ATP bioluminescent assay kit (FLAA, Sigma-Aldrich, Sydney, Australia) was used for 
estimation of ATP secretion in cell culture media samples.   
The sterile PBS solution used in all experiments consisted of 136.89 mM NaCl, 2.68 mM KCl, 
10.14 mM Na2HPO4, 1.76 mM KH2PO4 (all Sigma-Aldrich, Sydney, Australia) and was 
adjusted to pH 7.4. Sterile filtered water was sourced from a Milli-Q system (Millipore, 
Milford, MA, United States of America) and autoclaved at 121°C for 40 min. 
A cell lysis buffer (all reagents Sigma-Aldrich, Sydney, Australia) was used to lyse the cells at 
the end of the fluid shear stress experiment. The buffer comprised 10 mM Tris, 25 mM β-
glycerophosphate, 1 mM ethylenediaminetetraacetic acid (EDTA), 1% Triton X100, 1 mM 
DTT, 1 mM sodium orthovanadate (Na3VO4), 1 mM phenylmethylsulfonyl fluoride (PMSF), 





3.2. Culture of MLO-Y4 cells 
All cells were handled in a biological safety cabinet (BSC; Hera Safe 2020 1.2, Thermo Fisher 
Scientific, Auckland, New Zealand) in a physical containment level 2 (PC2) laboratory at 
Massey University, Palmerston North.   
Murine long bone osteocytes Y4 (MLO-Y4) cells, derived from transgenic mice (kindly gifted 
by Prof. Lynda Bonewald; Indiana Center for Musculoskeletal Health, Indianapolis, USA), 
were seeded on sterile collagen-coated 150 mm culture dishes (Nunc TM 168381, Thermo 
Fisher Scientific, Auckland, New Zealand) suspended in α-MEM medium, supplemented 
with 2.5% FBS, 2.5% CS and penicillin/streptomycin (PS) at 1%. Cells were grown in an 
incubator at 37°C with 5% CO2 until cells reached 70-75% confluence.  If growing cells from 
frozen stocks, α-MEM medium with 5% CS, 5% FBS with 1% PS was used. Cells were sub-
cultured when the cell culture reached 70-75% confluence and undertaken at a 1:5 sub-
culture of the trypsinised cell suspension. For regular cell passaging (sub-culturing) and 
maintenance, 30 ml of α-MEM containing 1.5 × 104 cells per ml was added to each 150 mm 
dish.  Cells were not used when the passage number exceeded 45. 
For fluid shear stress experiments requiring cells on collagen-coated glass slides, cells were 
seeded onto slides as follows.  The ”same” batch of cells were used for each experiment 
containing test and control cells. Forty-five ml of α-MEM supplemented with 2.5% FBS, 2.5% 
CS and PS at 1% containing 1.5 × 104 cells per ml was added to a 150 mm culture dish 
containing four collagen-coated slides (75 × 25 × 1 mm, Cat# 180626, Flexcell International 
Corporation, Burlington, NC, USA). Dishes were then covered and left in an incubator at 
37°C with 5% CO2 until cells reached 70-75 % confluence (6-8 days). 






3.3. Collagen coating of culture dishes and glass slides  
MLO-Y4 cells require a substrate coated with collagen I to express an osteocyte-like 
phenotype.  Sterile 150 mm culture dishes were coated with collagen by adding 15 ml of 
sterile collagen solution (Collagen I at 0.15 mg/ml in 0.02 M acetic acid).  For FSS 
experiments, collagen-coated glass slides were placed inside sterile 150 mm culture dishes. 
One ml of collagen solution (same as for 150 mm plates) was added to each glass slide to 
cover the exposed top surface of each slide.  
Culture dishes and slides were kept in the BSC for one hour at room temperature.  After 
one hour, any excess collagen was aspirated, and the dishes or slides were left to air dry in 
the BSC. When completely dry, coated dishes or those containing slides were sealed with 
paraffin tape, labelled and stored at 4°C for 1-2 months or used immediately. Prior to use, 
coated dishes and slides were washed with sterile PBS to remove any trace amounts of 
acetic acid. 
3.4. Lipid treatment studies for MLO-Y4 cells 
In order to expose MLO-Y4 cells to dietary fatty acids (FAs), FAs were solubilised in a solvent 
that could be added to the cell culture medium. Docosahexaenoic acid (DHA) and 
arachidonic acid (AA) were solubilised in 100% ethanol while palmitic acid (PA) was 
solubilised in 10 mM NaOH, heated to 70°C, with 10% BSA added when cool. Appropriate 
FA test concentrations that the MLO-Y4 cells were exposed to were previously determined 
by Léa Ribet (2017; unpublished results).  Briefly, cell viability was measured in MLO-Y4 cells 
exposed to a wide range of concentrations of either DHA, AA or PA.  Concentrations equal 
to or less than 20 μg/ml did not have any detrimental effect on cell viability and were 
therefore deemed appropriate for use with the cells. 
For the treatment of cells, DHA and AA were added at a concentration of 20 µg/ml to cells 




cells in control groups were treated with vehicle alone (solvent without FA). The amount of 
solvent vehicle present in culture with the cells was well below that previously documented 
as causing cytotoxicity or a loss of viability of the cells. All the cell groups with or without 
DFA containing media were cultured for five days in an incubator at 37°C with 5% CO2 prior 
to FSS experiment. 
3.5. Exposing MLO-Y4 cells to fluid shear stress (FSS) 
All fluid shear stress (FSS) experiments were conducted using a Flexcell StreamerTM device 
(Flexcell International Corporation, Burlington, NC, USA). The StreamerTM device, 
Masterflex L/S peristaltic pump (Cole-Palmer, USA), and associated tubing were purchased 
from Flexcell International Corporation and the standard configuration of the fluid flow 
experiment can be seen in Figure 3-1. 
The associated tubing and their measurements were as follows: two lengths of silicone 
tubing (length 0.6 m), one length (0.9 m) of Phar Med tubing and one length of silicone 
tubing (0.076 m). 
Fluid shear stress experiments were conducted in a cell culture incubator (Heracell 150i, 
Thermo Fisher Scientific, Auckland, New Zealand). The Streamer device and Masterflex 
pump were placed in the incubator (37°C, 5% CO2) for at least 20 minutes before starting 
an experiment to equilibrate the temperature and gas environment of the system and 
solutions. Prior to this, sterile PBS was run through the fluid circuit in the apparatus for 
several minutes to flush the system before the PBS was discarded, and the device was run 
with fresh medium to displace the PBS. 
Six slides covered with adherent MLO-Y4 cells on one side were inserted into the 
StreamerTM device in the following manner.  Briefly, the flow of the medium in the circuit 
was reversed so that the top 20% of the streamer was void of the medium. This minimised 




slides were inserted into the device, the lid of the device was replaced and bolted in place, 
and fluid flow was restored in the correct direction. This method was found to be effective 
in eliminating any bubbles trapped inside the inlet or outlet ports on the StreamerTM. Fluid 
shear stress values of 0 to 20 dyn/cm2 were used for two hours duration for the dose and 
time response experiment, whereas 1 to 20 dyn/cm2 were used for dietary fatty acid 
treatment experiments. Cells at 0 dyn/cm2 were placed in culture dish with fresh media and 
same environment similar to test for duration of time and were not exposed to fluid shear 
stress. The 0 dyn/cm2 treatment was also replaced in dietary fatty acids treatment 
experiments with 1 dyn/cm2 as we discovered a minimal amount of fluid movement in the 
StreamerTM circuit was important to collect media that the cells had been exposed to. We 
found that 30 minutes of time was the optimal duration time for the lipid treatment study 
so that sampling time was used for subsequent experiments. Cells treated with FA and in 
the absence of FA were exposed FSS of 1 or 20 dyn/cm2. Samples of cell culture media 
circulating in the Flexcell StreamerTM device were collected at 0, 5 and 30 minutes after the 
commencement of FSS. 
Samples of cell culture medium were collected at the time points described above to allow 
quantification of ATP secretion by the MLO-Y4 cells. Briefly, 1 ml samples of cell culture 
medium were collected at each sample time during fluid shear stress experiment using a 
sterile 1 ml syringe inserted into the length of silicone draining the StreamerTM device, this 
was done for both test and control treatments. All samples of cell culture medium were 
kept on ice and centrifuged at 10,000 g for 2 min at 4°C to remove any cellular debris and 
the supernatant was snap-frozen and stored at -80°C until further analysis.  
At the end of each experiment, MLO-Y4 cells on all slides were either treated with 1ml of 
0.05% Trypsin EDTA for cell counting or treated with 500 µl of ice-cold lysis buffer for protein 
extraction. An aliquot of the cell suspension was diluted (10-fold) in 0.2% Trypan Blue 




Lysed cells were scraped off the slides and collected along with the lysis buffer into 
individual Eppendorf tubes for each treatment. Sample tubes were kept on ice and then 
centrifuged at 15,000 g for 15 min at 4°C. The supernatants were collected and frozen at -
80°C for further analysis.   
 
Figure 3-1:  1) Outline of the streamer device system.   
A. Cell culture media reservoir bottle, B. Silicone tubing,  C. Phar Med tubing, D. 
Masterflex peristaltic pump, E. Pulse Dampner #1, F. Silicone Tubing, G. Pulse 
Dampner #2, H. Silicone tubing, I. Inlet port, J. Outlet port, K. StreamerTM device.  
Arrow indicates the direction of fluid flow. 2) StreamerTM device in operation. 
(Adapted from: Flexcell Streamer Users Manual, April 2011). 
3.6. ATP assay 
ATP was measured in cell culture medium samples collected from MLO-Y4 cells exposed to 
FSS or controls as has been previously described [38, 135, 258].  The method of quantifying 
ATP uses an assay that is based on the Luciferin-Luciferase reaction.  This assay technique 
is based on the luciferases requirement for ATP in producing light (emission maximum ~560 
nm at pH 7.8).    
The concentration of ATP secreted into the cell culture media was measured using a 
commercially available ATP bioluminescent assay kit (FLAA, Sigma-Aldrich, Auckland, New 




consisting of lyophilized powder containing luciferase, luciferin, magnesium sulphate 
(MgSO4), 1,4-dithiothreitol (DTT), ethylenediaminetetraacetic acid (EDTA), bovine serum 
albumin (BSA), and tricine buffer salts and (3) an ATP assay buffer (FL-AAB): lyophilized 
powder containing MgSO4, DTT, EDTA, BSA, and tricine buffer salts. 
Briefly, one vial of ATP assay mix was mixed with 5 ml of sterile Milli-Q water and mixed 
gently until dissolved and then kept on ice for at least one hour. The ATP assay mix solution 
was then aliquoted into smaller volumes and frozen for future use. This solution was stored 
at 4°C for up to 2 weeks.  
In preparation for measuring ATP in samples, an undiluted vial of ATP assay dilution buffer 
was dissolved in 50 ml of sterile Milli-Q water and aliquoted into five 10 ml glass test tubes.  
A suitable volume of thawed ATP assay mix was then mixed with the ATP assay dilution 
buffer in a 25-fold dilution.  This dilution rate permits an ATP detection range of 2×10-10 to 
2×10-7 moles/litre (as recommended in the manufacturer’s protocol).  An ATP standard 
curve was created by making a serial dilution of the supplied ATP standard (3.90, 7.81, 
15.625, 31.25, 62.5, 125, 250, 500, 1000 nM).  
ATP assays were conducted in flat-bottomed 96 well plates.  One hundred µl of ATP assay 
mix diluted in ATP dilution buffer was dispensed to the required number of wells.  Following 
this, 100 µl of each ATP standard (including a blank) and unknown samples were added to 
wells containing ATP assay mix.  All standard and unknown samples were analysed using 
four replicates including a blank containing ATP assay dilution buffer.  The assay plate was 
then placed on an orbital shaker and allowed to gently mix at room temperature (RT) for 3 
min. After 3 min, the luminescence signal of the plate was measured using a luminometer 
plate reader (Fluoroskan Ascent FL, Thermo Fisher Scientific, Auckland, New Zealand). The 
luminance values were used to generate a standard curve which could be used to determine 




ATP from unknown samples were conducted using Microsoft Excel (2010) and GraphPad 
Prism 5 (GraphPad Software, San Diego, CA, USA). 
3.7. Counting of cells 
Cells were briefly washed using the 1XPBS while still on the slides. Cells were treated with 
1 ml of 0.05% Trypsin EDTA and placed in an incubator at 37°C in 5% CO2 for 5 min. The 
detached cells were collected in a vial and diluted (10-fold) with 0.2% Trypan Blue. Cell 
numbers were then measured using a haemocytometer.  Using the cell number for each 
sample, the amount of ATP secreted was expressed per million cells. 
3.8. Protein assay 
The protein concentrations of the cell lysates collected from FSS experiments was measured 
using the Bio-Rad DC protein assay kit (Bio-Rad, Cat# 500-0116). This is a colourimetric assay 
for protein concentration following detergent solubilisation. The overall principle is similar 
to the Lowry assay [259] but with a few modifications. Briefly, the assay is based on the 
reaction of protein with an alkaline copper tartrate solution and Folin reagent. As with the 
Lowry assay, there are two steps which lead to colour development: the reaction between 
protein and copper in an alkaline medium, and the subsequent reduction of Folin reagent 
by the copper-treated protein [259]. Colour development is primarily due to the amino 
acids tyrosine and tryptophan, and to a lesser extent, cystine, cysteine, and histidine [259, 
260]. Proteins affect the reduction of the Folin reagent by loss of one, two or three oxygen 
atoms, thereby producing one or more of several possible reduced species which have a 
characteristic blue colour with maximum absorbance at 750 nm and minimum absorbance 
at 405 nm.  
For determining the protein content of cell lysates, serial dilutions (31.25, 125, 250, 500, 




the assay reagents before the absorbance was measured using a Nanophotometer p300, 
Implen. Colourimetric data was plotted for the concentration of protein against absorbance 
and used to create standard curves. Then the protein content of unknown cell lysate 
samples was determined using this standard curve. Normalization of ATP values measured 
in cell culture medium samples was undertaken using the protein values obtained for each 
sample.  Any variations in protein content in each sample due to differences in total cell 
lysate volume were corrected by multiplying protein concentration with the volume of 
lysate collected. Then the amount of ATP was divided by the amount of protein to get an 
amount of ATP per mg of protein.  
3.9. Statistical analysis 
The statistical analysis was done using Microsoft Excel (2010) and GraphPad Prism 5 
(GraphPad Software, San Diego, CA, USA). Student T-tests and analysis of variance 
(ANOVA)were performed to compare between fatty acid treatment, fluid shear stress and 
time. Means and standard errors were calculated and analysed between different 




Chapter 4. Results 
4.1. Introduction 
Mechanical loading is a crucial factor in the maintenance of bone homeostasis and 
structure. Bone cells, in response to mechanical loading release signalling molecules and 
participate in the bone remodelling process. These signalling molecules stimulate a range 
of other bone cells such as osteoblasts, which enhances the bone formation process. 
Osteocytes are one of the key players in this process as they have a larger population and 
deeply embedded habitat. These cells are sensitive to mechanical loading and secrete 
different signalling molecules in response to mechanical loading. Depending on the level of 
physical and mechanical activity or shear stress, these secreted molecules activate cell 
signalling pathways in osteoblasts and osteocytes in a process called mechanotransduction. 
People who are physically inactive or in induced microgravity have shown diminished bone 
structure because of reduced mechanical loading they bear in their skeleton [261, 262]. 
Studies show that dietary supplementation of omega 3 and 6 fatty acids is beneficial in 
maintaining bone health but the exact mechanism is unclear [236, 263]. The role of these 
fatty acids in the release of ATP by fluid shear stressed were studied on MLO-Y4 cells. The 
main objective of the study was to check the effect of different dietary fatty acids, mainly 
DHA and AA on the secretion of ATP by MLO-Y4 cells in response to fluid shear stress. The 
general hypothesis of the study was that the dietary fatty acids, more specifically omega-3 
(DHA) and omega-6 (AA) might have a positive effect on bone health when combined with 
physical activities. To test this we treated MLO-Y4 cells with different fatty acids and 
measured the level of ATP secreted by these cells due to increased mechanotransduction 





4.2. Method development 
It is very difficult to create an environment similar to that experienced by osteocytes in vitro. 
However, the MLO-Y4 osteocytic cell line was chosen and treated with different FA in a 
simulated environment in vitro. MLO-Y4 cells were exposed to different degrees of fluid 
shear stress and the cell culture medium collected for evaluation of secreted ATP. By doing 
this, this study tried to find out if the treatment of MLO-Y4 cells with different fatty acids 
under fluid shear stress had any role in the modulation of ATP secretion.  
4.3. Calibration of flow rate 
Calibration of the flow rate through the Flexcell Streamer fluid circuit by a peristaltic pump 
was done every time before starting a new experiment. It was done to evaluate the accuracy 
of the pump. The accuracy of the pump to deliver a known flow rate through the fluid circuit 
was checked. The volume of water passing through the circulation and pump for a set time 
point was measured with a certain flow rate. We then cross-checked the volume of water 
with expected volume specified in the instrument manual. Manual suggested a list of flow 
rate based on the amount of shear stress required. Any fluctuation in the volume was 
corrected by adjusting the flow rate in the pump. For example, we needed 10 ml per minute 
of flow rate to get 5 dyn/cm2 of shear stress as suggested by the manual. We set pump for 
10 ml/min and checked the volume. We found out that the device was pumping 13 ml per 
min. When we set the flow rate to 8 ml/min, the device was pumping 10 ml/min which was 
required to get 5 dyn/cm2 of shear stress. In such a manner other shear stress values were 
established by correcting the flow rate and used for our study.  
4.4. Dilution adjustment 
Initial experiments showed that the alpha MEM medium contained Phenol red and other 
unknown inhibitory substances that affected the ATP assay so the MEM medium was 




the assay as shown in Figure 4-1. For the 1,000 nM ATP standard, the assay luminance 
increased with the increasing dilution with water. Standard is not diluted but the medium 
on which standard prepared is diluted. In our case, we prepared 1000 nM of standard in 
several tubes with different dilutions of the medium with water. We found that increasing 
the water composition in the medium increased the luminance. Which implied that there 
was some unknown substance that inhibited luminance. In subsequent experiments, 
samples were diluted 2:8 (or 1:4) as this dilution had luminance similar to the 1:9. As this 
experiment was mostly based on detecting ATP in the collected medium, diluting 1:9 
would have possibly made it too dilute and 2:8 would fairly represent the amount of ATP. 





Figure 4-1: ATP standard with concentration 1000 nanoMolar (nM) at various dilutions of 
medium.  
The 1000 nM ATP standard prepared with various dilutions of cell culture medium with 
water. Then the luminance of the ATP of the various 1000 nM solutions was measured. 
From left to right on the X-axis is the ascending ratio of the water content. The luminance 
was seen lowest in the medium solution where there is no water content and highest in 
the dilution where there is no medium. Levels not connected by the same letter were 
significantly different. All data were mean ± SEM, n=3.  
 














































Figure 4-2: A typical standard curve for ATP assay.  
Various concentrations of ATP were prepared by diluting a 1,000 nM standard into 
various concentrations. Then these standard solutions were checked for the luminance 
using a luminometer. A standard curve was prepared every time during a new ATP assay. 






4.5. Effect of fluid shear stress on the secretion of ATP by MLO-Y4 cells 
Weinbaum et al [41] estimated the magnitude of the mechanical loading-induced fluid 
shear stress sensed by osteocytic processes to be in the range between 8 and 30 dyn/cm2. 
A fluid movement system was created in vitro similar to fluid shear stress experienced by 
the osteocytes in vivo in a normal and loading condition. This part of the study sought to 
determine how the magnitude of fluid shear stress might influence ATP secretion in the 
chosen test system using MLO-Y4 cells. So the effect of fluid shear stress on ATP secretion in the 
medium by MLO-Y4 cells was checked. Fluid shear stress (FSS) in vivo experienced by the 
osteocytic processes ranges from 0-30 dyn/cm2 [41], so MLO-Y4 cells were exposed to FSS 
and ATP secretion by MLO-Y4 cells in the medium exposed to FSS ranging from 0, 5, 10, 20 
and 30 dyn/cm2 was measured (Figure 4-3). The amount of ATP measured in the cell culture 
medium increased with the magnitude of FSS. ATP amounts in the medium were relatively 
constant in the control cells not exposed to FSS (0 dyn/cm2) for 30 minutes. ATP increased 
within 5 minutes of FSS in cells exposed to 5-30 dyn/cm2. ATP increased 3.75 - 4.94 nmol/106 
cells at 2, 15 and 30 min in cells exposed to 5 dyn/cm2. ATP increased to the range of 5.20 
to 6.51 nmol/106 cells at 2, 15 and 30 min in cells exposed to 10 or 20 dyn/cm2.  ATP 
amounts were significantly higher in medium collected from cells exposed to 30 dyn/cm2 
increasing to 6.71 nmol/106 cells at 2 min and then to 8.83 and 9.07 nmol/106 cells at 15 
and 30 min respectively.  
There were no significant differences in the ATP in the medium collected at 10 and 20 
dyn/cm2 at any time point. The highest amount of ATP was seen in the medium collected 
from the cells exposed to 30 dyn/cm2 which is significantly higher compared to ATP 
collected from 5 and 10 dyn/cm2 at 2, 15 and 30 minutes. The ATP collected from the cells 
exposed to 30 dyn/cm2 were also higher compared to 20 dyn/cm2 in all time points except 




The amount of ATP in the medium across the FSS treatments at 2 min after the onset of 
FSS is shown in Figure 4-4. ATP amount were significantly elevated above the control at 5, 
10, 15 and 30 min in a dose-dependent manner.  
In these results, fluid shear stress was shown to stimulate the MLO-Y4 cells to secrete ATP. 
ATP was released within 2 minutes of the cells being exposed to fluid shear stress and the 
amount released remained steady for the duration of the exposure. Increasing the rate of 
fluid flow was found to increase the amount of ATP. At 2 minutes, amount of ATP at 0 
dyn/cm2 was significantly lower than the amount of ATP at 10, 20 and 30 dyn/cm2 (P<0.05). 
The amount of ATP was increased in 5 dyn/cm2 but the difference was not found to be 
statistically significant compared to 0 dyn/cm2.  
4.6. Time course of ATP release 
In the dose-response experiment, the amount of ATP released was found to be greatest in 
cells exposed to 30 dyn/cm2 and lowest in 0 dyn/cm2. Weinbaum et al [37] estimated the 
magnitude of the mechanical loading-induced fluid shear stress sensed by osteocytic fluid 
movement processes to be in the range between 8 and 30 dyn/cm2. The similar fluid 
movement comparable to the osteocytic environment in vitro was replicated and ATP 
secretion was measured in media collected from MLO-Y4 cells exposed to fluid shear 
stress. A fluid flow rate of 20 dyn/cm2 was used for fluid shear experiments and not 30 
dyn/cm2 as this is at the upper borderline of the range that the osteocytic processes can 
experience in vivo. Also, 20 dyn/cm2 gave a robust response but not at the maximum of 
the physiological range, thus allowing us to determine if cell treatments with fatty acids 
can decrease or increase the response.  
The effect of exposure time on fluid shear stress on the ATP secretion by MLO-Y4 cells is 
shown in (Figure 4-5). The amount of ATP measured in the cell culture medium increased 




at an 11.73 ± 4.57 nmol/106 cells throughout the two hours of FSS. ATP secretion did not 
change and remained constant at 1.59 ± 0.79 nmol/106 cells in the medium collected from 
control cells (0 dyn/cm2). Higher amounts of ATP were observed at the 0 time point for 
the test. The reason for this was collection of the media at the start of the streamer 
device. It is possible to assume that immediately after running the device, fluid shear 
stress causes the MLO-Y4 cells to secrete the ATP. Analysis of the data showed that there 
were no significant differences in the amount of ATP secreted by the cells exposed and 
not exposed to FSS. 
This was the primary experiment conducted to standardize the system and subsequent 
experiments. This experiment helped us to choose an optimal dose (20 dyn/cm2) and time 







Figure 4-3: Figure showing the effect of various dosages of shear stress on ATP secretion 
in MLO-Y4 cells.  
These cells were divided into five groups on the fluid shear experiment days based on 
the various fluid shear stress applied on MLO-Y4 cells, such as 0, 5, 10, 20 and 30 
dyn/cm2. Media samples were collected at 0, 2, 15 and 30 minutes and ATP was 
measured using the Luciferin-Luciferase assay. Letters at each time point indicate 
significance, where differences between letters at two points indicate significance  
(P<0.05). All data were mean ± SEM, n=3.  












































Figure 4-4:  The effect of fluid shear stress on ATP secretion by MLO-Y4 cells in two 
minutes time point.  
MLO-Y4 cells were divided into five groups on the basis of fluid shear stress they 
experienced, such as 0, 5, 10, 20 and 30 dyn/cm2. ATP was measured using Luciferin-
Luciferase assay in the collected media samples. Levels not connected by the same 
letters were significantly different (P<0.05). All data were mean ± SEM, n=3. 



































Figure 4-5: Detailed and extended time course graph showing the effect of fluid shear 
stress on MLO-Y4 cells for 120 minutes on ATP secretion.  
MLO-Y4 cells were divided into two groups and exposed to either 0 dyn/cm2 or 20 
dyn/cm2 for two hours. Samples of the medium were collected at the time points 
indicated in the figure. The medium was analysed for secreted ATP using the Luciferin-
Luciferase assay. ATP values were normalised to the number of cells. All data were mean 




4.7. Effect of Docosahexaenoic acid (DHA) on ATP secretion from MLO-Y4 cells exposed 
to fluid shear stress. 
Omega 3 fatty acids, mainly DHA, are good for bone health in animals. There are studies 
on the effect of DHA and AA on other bone cells but no information on the secretion of 
ATP by osteocytes. To determine if the DHA has any effect on ATP secretion by osteocytes, 
osteocytes were treated with DHA at a concentration of 20 μg/ml, and its effect on ATP 
secretion was measured. MLO-Y4 cells cultured on slides were treated with DHA or 
without DHA containing medium for five days. The cells were exposed to fluid shear stress 
for thirty minutes on the day of the experiment as described previously in the methods 
section (Chapter 3). Both cell groups with or without DHA were exposed to 1 dyne/cm2 
and 20 dyn/cm2 of FSS and medium was collected at 0, 5 and 30 minutes. The amount of 
ATP was determined by Luciferase assay. The effect of DHA on ATP secretion from MLO-Y4 
cells exposed to fluid shear stress is shown in Figure 4-6. 
At 0 minutes no significant differences were found among the DHA treated and non-DHA 
treated cells whether they were exposed to fluid shear stress or not.  
ATP secretion in DHA treated cells exposed to 1 dyn/cm2 rose from 0.77 ± 0.39 nmol/mg of 
ATP at 0 minutes to 2.47 ± 0.56 nmol/mg at 5 minutes. ATP secretion in DHA treated cells 
exposed to 20 dyn/cm2 rose from 2.38 ± 1.63 nmol/mg at 0 minutes to 20.23 ± 9.33 
nmol/mg protein in 5 minutes.  Similarly ATP secretion in control cells treated to 1 dyn/cm2 
found to be 0.58 ± 0.55 nmol/mg of ATP at 0 minutes which rose to 1.51 ± 0.31 nmol/mg of 
ATP at 5 minutes whereas ATP secretion in control cells exposed to 20 dyn/cm2 rose from 
1.23 ± 1.13 nmol/mg at 0 minutes to 6.64 ± 0.38 nmol/mg of ATP in 5 minutes. The DHA 
treated cells exposed to 20 dyn/cm2 had significantly higher (P<0.05) ATP secretion 
compared to all controls and DHA 1 dyn/cm2 treated cells at 5 minutes. There were no 




At 30 minutes DHA treated cells exposed to 1 dyn/cm2 remained steady at 2.58 ± 0.99 
nmol/mg whereas DHA treated cells exposed to 20 dyn/cm2 remained steady at 20.28 ± 
10.74 nmol/mg. Control cells exposed to 1 dyn/cm2 settled at 1.17 ± 0.03 nmol/mg from 
1.51 ± 0.31 nmol/mg at 5 min similarly Control cells exposed to 20 dyn/cm2 settled at 6.00 
± 0.77 nmol/mg from 6.64± 0.38 nmol/mg at 5 min. DHA treated cells exposed to 20 
dyn/cm2 had significantly higher (P<0.05) ATP secretion compared to all controls and DHA 
1 dyn/cm2 treated cells at 30 minutes time point similar to 5 minutes. There were no 
differences among control 1 dyn/cm2, control 20 dyn/cm2 and DHA 1 dyn/cm2 cells at 30 
minutes. 
Interestingly there were no significant differences in ATP secretion in DHA treated cells 
exposed to 1 dyn/cm2 and control cells exposed to 20 dyn/cm2 at any point of time. 
Similarly, there were differences between control cells exposed to 1 dyn/cm2 and 20 
dyn/cm2 but they were found to be not statistically significant (P>0.05). 
In conclusion, the treatment of DHA significantly enhanced the ATP secretion from MLO-Y4 









Figure 4-6: Figure showing the effect of docosahexaenoic acid (DHA) on ATP secretion 
by MLO-Y4 cells exposed to fluid shear stress.  
MLO-Y4 cells were divided into two groups. The test cells, which were treated with 20 
μg/ml of DHA and control cells which were treated with vehicle control. Then MLO-Y4 
cells were exposed to fluid flow for 30 minutes at 1 dyn/cm2 and 20 dyn/cm2. The 
medium was collected at various time points 0, 5 and 30 minutes. After the experiment, 
the collected medium was assayed for ATP using the Luciferin-Luciferase assay. Levels 
not connected by the same letters were significantly different (P<0.05). All data were 




4.8. Effect of Arachidonic acid (AA) on ATP secretion 
After investigating the effect of an omega 3 fatty acid on ATP secretion, the effect of an 
omega 6 fatty acid was compared. The effect of the omega 6 FA arachidonic acid (AA) on 
ATP secretion in MLO-Y4 cells exposed to fluid shear stress is shown in Figure 4-7. MLO-Y4 
cells were categorised to control (AA non-treated) or test (AA treated) cells which were both 
exposed to 1 dyne/cm2 and 20 dyn/cm2. 
At 0 minutes no significant differences were found among the AA treated and control cells 
at any shear stress. The fluid shear stress did not affect ATP secretion at 0-minute time 
point. 
At 0 minutes, 0.10 ± 0.03 nmol/mg of protein of ATP was secreted by AA treated cells 
exposed to 1 dyn/cm2 which rose to 0.12 ± 0.07 nmol/mg of protein at 5 minutes and settled 
at 0.16 ± 0.12 nmol/mg of protein at 30 minutes. ATP secretion in AA treated cells exposed 
to 20 dyn/cm2 rose from 0.55 ± 0.21 nmol/mg at 0 minutes to 5.42 ± 3.88 nmol/mg in 5 
minutes which then settled at 4.08 ± 3.05 nmol/mg at 30 minutes. Similarly, 0.19 ± 0.29 
nmol/mg of protein of ATP was secreted by control cells exposed to 1 dyn/cm2 which rose 
to 1.10 ± 0.54 nmol/mg of protein and settled to 0.53 ± 0.32 nmol/mg of protein at 30 
minutes. Whereas ATP secretion in control cells exposed to 20 dyn/cm2 rose from 0.24 ± 
0.31 nmol/mg of protein at 0 minutes to 2.43 ± 1.33nmol/mg of protein in 5 minutes which 
settled to 2.88 ± 1.87 nmol/mg of protein at 30 minutes. 
There were no significant differences in ATP secretion between AA treated cells exposed to 
1 dyn/cm2 and control cells exposed to 1 dyn/cm2 at any point in time.  
When compared between ATP secretion in control cells treated with 1 dyn/cm2 and 20 
dyn/cm2, significant differences (<0.05) were observed at the 30 minute time point but no 




between AA treated cells exposed to 20 dyn/cm2 and control 20 dyn/cm2 was observed at 
5 minutes but not at 0 and 30 minutes. 
A significant difference (P<0.05) in ATP secretion was observed at 5 and 30 minutes for 
groups of AA treated cells exposed to 1 dyn/cm2 and 20 dyn/cm2. ATP secretion among AA 
treated cells exposed to 1 dyn/cm2 and control cells exposed to 20 dyn/cm2 were also found 
to be significantly different (P<0.05) at 5 minutes and 30 minutes. A similar trend was seen 
when comparing ATP secretion in AA treated cells exposed to 20 dyn/cm2 and control cells 
exposed to 1 dyn/cm2 which were significantly different (P<0.05) at 5 and 30 minutes time 
points. However, at the 0-minute time point, there were no significant differences. 
In conclusion, AA treatment enhanced ATP secretion in MLO-Y4 cells exposed to fluid shear 







Figure 4-7:  Figure showing the effect of arachidonic acid (AA) on ATP secretion by MLO-
Y4 cells exposed to fluid shear stress.   
MLO-Y4 cells were divided into two groups, test cells which were treated with 20 μg/ml 
of AA and control cells which were treated with vehicle control. Then MLO-Y4 cells were 
exposed to fluid flow for 30 minutes at 1 dyn/cm2 and 20 dyn/cm2. The medium was 
collected at various time points 0, 5 and 30 minutes. After the experiment, ATP was 
measured in the collected medium using the Luciferin-Luciferase assay. Levels not 
connected by the same letters were significantly different (P<0.05). All data were mean 




4.9. Effect of Palmitic acid (PA) on ATP secretion. 
MLO-Y4 cells were also treated with palmitic acid to see whether the enhanced amount of 
ATP seen on treatment with DHA and AA was due to the addition of the carbon chain or the 
nature of the fatty acids in the culture medium. Figure 4-8 shows the effect of palmitic acid 
on ATP secretion in MLO-Y4 cells exposed to fluid shear stress. The experiment suggests 
that there were differences in the ATP secretion between higher fluid shear stress (20 
dyn/cm2) and lower shear stress groups (1 dyn/cm2) however, there was no effect of 
palmitic acid on ATP secretion. Both PA treated and the non-treated group had a similar 
trend in ATP secretion in both higher shear stress and lower shear stress.  
At 0 minutes, 0.18 ± 0.22 nmol/mg of protein of ATP was secreted by PA treated cells 
exposed to 1 dyn/cm2 which rose to 0.72 ± 0.67 nmol/mg of protein at 5 minutes and settled 
at 0.81 ± 0.75 nmol/mg of protein at 30 minutes. ATP secretion in PA treated cells exposed 
to 20 dyn/cm2 rose from 0.26 ± 0.07 nmol/mg at 0 minutes to 6.40 ± 4.56 nmol/mg in 5 
minutes which then settled at 5.93 ± 6.81 nmol/mg at 30 minutes. Similarly, 0.19 ±0.19 
nmol/mg of protein of ATP was secreted by control cells exposed to 1 dyn/cm2 which 
lowered to 0.89 ± 1.26 nmol/mg of protein and settled to 1.13 ± 1.19 nmol/mg of protein 
at 30 minutes. Whereas ATP secretion in control cells exposed to 20 dyn/cm2 rose from 0.39 
± 0.82 nmol/mg of protein at 0 minutes to 4.77 ± 3.61 nmol/mg of protein in 5 minutes 
which settled to 5.88 ± 3.77 nmol/mg of protein at 30 minutes. 
There were significant differences (P<0.05) between PA treated cells exposed to 20 dyn/cm2 
and 1 dyn/cm2. There was also a significant difference (P<0.05) between control cells 
exposed to 20 dyn/cm2 and 1 dyn/cm2. There were no significant differences among the PA 
treated cells and control cells at 20 dyn/cm2 or 1 dyn/cm2.  
The fact that the differences remained in the groups of cells between higher and lower 




was the result of fluid shear stress and not the PA treatment. Thus, palmitic acid didn’t 
affect ATP secretion in MLO-Y4 cells exposed to fluid shear stress, unlike AA or DHA which 
enhanced the secretion of ATP in response to FSS. These results indicated that the release 
of ATP observed in DHA and AA treated cells in response to FSS are specific and not general 
effect from addition of any fatty acids.  
 
Figure 4-8: Figure showing the effect of Palmitic acid on ATP secretion by MLO-Y4 cells 
exposed to fluid shear stress.  
MLO-Y4 cells were divided into two groups, test cells which were treated with 0.2 mM PA 
and control cells which were treated with vehicle control. MLO-Y4 cells were exposed to 
fluid flow for 30 minutes at 1 dyn/cm2 and 20 dyn/cm2. The medium was collected at 
various time points 0, 5 and 30 minutes. After the experiment, ATP was measured using 
the Luciferin-Luciferase assay. Levels not connected by the same letters were significantly 





Chapter 5. Discussion 
Mechanical loading, in general, plays a very important role in the maintenance of the 
skeleton. It induces various biochemical signals at the molecular and cellular levels. The 
distribution and number of osteocytes in bone is such that it is considered the principal 
mechanosensor in the bone. It communicates the signal received by bone due to exercise 
to the various cells such as osteoblasts, osteoclasts, bone lining cells and other osteocytes 
in a form of biochemical response. It is believed that the release of ATP is one of the 
responses by which osteocytes respond to the mechanical signal. 
5.1. Does fluid shear stress affect ATP secretion? 
Fluid shear stress stimulated ATP secretion by MLO-Y4 cells when compared to the non-
fluid shear stress treated MLO-Y4 cells. The relationship between the applied FSS and ATP 
secretion in MLO-Y4 cells is shown in Figure 4-3, which indicated that as the fluid shear 
stress increased, the amount of ATP secreted also increased. Minimal ATP secretion was 
observed at 0 dyn/cm2 whereas a higher amount of ATP was secreted at 30 dyn/cm2. 
Similarly, increased ATP secretion was observed between 10 and 20 dyn/cm2. The amount 
of ATP released was significantly higher in 30 dyn/cm2 compared to 0 dyn/cm2 (Figure 
4-4). Although not statistically significant, cells exposed to 5 dyn/cm2 also had higher ATP 
secretion compared to the 0 dyn/cm2. The mechanism for the secretion of higher ATP in 
MLO-Y4 cells exposed to higher fluid shear stress is yet unknown however an earlier study 
suggested a role for membrane permeability. A study by Genetos et al., showed FSS 
induced ATP release in MC3T3-E1 cells was found to be dependent on ca2+ channel and 
the transport was vesicular release and not through hemichannel [38].  In the study by 
Berthiaume et al., shear stress caused an increase in membrane permeability of human 
endothelial cells which caused the uptake of amphipathic dye merocyanine 540 by a 




expansion in membrane fluidity [264]. Analysing these facts, enhanced ATP secretion from 
the cells might be due to vesicular transport which might be improved by the membrane 
fluidity. However, there is no evidence for this yet. Cell viability assay and alkaline 
phosphatase test might have further added strength to the results indicating that the ATP 
release was due to fluid shear stress and not because of cell destruction. 
5.2. Does the duration of fluid shear stress affect ATP secretion? 
ATP secretion by MLO-Y4 cells exposed to fluid shear stress for 120 minutes is shown in 
Figure 4-5. Within one minute of exposure, the ATP was secreted by MLO-Y4 and remained 
constant for the entire period. The peak ATP was observed at 120 minutes, but the overall 
amount remained similar throughout the period. This might be due to the cell membrane 
permeability that was opened after the first few minutes of the fluid shear stress remained 
entirely similar and fluctuated only after the prolonged exposure period. A relatively higher 
amount of ATP was detected at 120 minutes possibly due to the constant opening of the 
hemichannels leading to increases in the pore sizes and allowing more secretion of ATP at 
this point.  
5.3. Does treating cells with different types of fatty acids affect the ATP secretion?  
Under conditions considered optimal for cell growth, DHA and AA at a concentration of 20 
µg/ml had a significant effect on the secretion of ATP by MLO-Y4 cells during the fluid 
shear stress however PA had no significant effect on the same process. ATP secretion in 
MLO-Y4 cells was enhanced by the treatment with DHA and AA following the fluid shear 
stress (Figure 4-6 and Figure 4-7). But PA had no significant effect on the secretion of ATP 
after fluid shear stress (Figure 4-8). It indicated that there was some relationship between 
the nature of the fatty acid added to the culture medium and its effect on ATP secretion 
by MLO-Y4 cells exposed to FSS. It appeared that FA composition of the membrane had 




membrane resulted in differences in the secretion pattern of ATP after the fluid shear 
stress by different treatment groups. Saturated FA had no differences on ATP secretion in 
FSS treated osteocytes whereas unsaturated FA increased the ATP secretion in FSS treated 
osteocytes. 
PUFAs in general, have two main functions in human cells. Apart from being precursors for 
eicosanoids which can act as autocrine and paracrine regulators in the body, they contribute 
to the synthesis of phospholipids in the lipid bilayer of the cell membrane which results in 
a fluid mosaic structure. In a cell membrane, hydrophilic head and hydrophobic tails of 
phospholipids arrange in such a way that they appear as a fluid mosaic which gives the 
membrane a fluid-like structure. Membrane permeability is influenced by various factors, 
including changes in lipid composition, the concentration of cell membrane cholesterol, the 
density of lipid packing, relative water content, ion concentration, pH, and temperature, 
and shear stress may alter membrane lipid order via any of these factors or combinations 
of them. Dietary fat modification can lead to changes in the fatty acid composition of 
membrane phospholipids [265]. The nature of the lipids in the membrane has an impact on 
the fluidity of the particular membrane. Salem et al showed that polyunsaturated FA are 
present in the plasma membrane and around membrane-bound protein [266]. High 
concentrations of PUFA in membranes has a significant effect on membrane fluidity [267].  
Unsaturated FA have several double bonds which make them loosely packed in the fluid 
mosaic model of the cell membrane which increases the ability of the membrane to bend 
readily due to cis bonds and prevents the molecular interaction among the FA chains in the 
membrane. This helps to maintain the fluidity in the cell membranes. Studies on living cells 
and membrane models have shown that the cholesterol content of the membrane has a 
major impact on the physical properties of plasma membranes, including on their 
membrane fluidity [268, 269]. On the other hand, a saturated fatty acid having no double 




membrane. Alam et al showed that trans FA in the diet decreased membrane fluidity in the 
plasma membrane of lacrimal glands [270]. Cooper et al modified red blood cell membrane 
structure by incorporating cholesterol-rich lipids [271] and found it to have several 
abnormalities including decreased membrane fluidity [272]. However, an increase in 
phosphatidylcholine/sphingomyelin ratio was associated with increased erythrocyte 
membrane fluidity [273, 274]. Incorporating hydrophobic cholesterol in the membrane 
might have decreased membrane fluidity and incorporating more hydrophilic 
phosphatidylcholine increased membrane fluidity. Concerning these studies, the saturated 
FA having hydrophobic carbons tightly packed with each other prevent other compounds 
to move into the membrane. On the other hand, unsaturated FA having one or multiple 
double bonds, might have allowed it to be less hydrophobic compared to saturated FA.  
Genetos et al demonstrated that fluid shear stress-induced the opening of the 
hemichannels responsible for ATP release in osteocytes [275]. This might be one of the 
possible reasons as to why there was higher ATP secretion in PUFA treated MLO-Y4 cells 
compared to non-treated MLO-Y4 cells. Administration of fatty acid in the cell medium 
might have influenced the cell membrane fluidity causing variation in the ATP secretion 
among different fatty acids group. There was some association of FA treatment with ATP 
release [276, 277].  
There is clearly no data available that present the effect of FA on mechanotransduction of 
osteocytes. There are some studies which treated the cells with mechanical loading and 
assessed their biochemical response [29, 33, 278-280] but not in combination with the FAs. 
This present study presented a novel approach to study the behaviour of cells in response 
to FSS after the treatment of the cells. These results indicate that the ATP secretion in cells 
was affected by the nature of FA treatment and these FA might be used to study 
biochemical response in the mechanotransduction studies. These results showed for the 




stress. These extracellular ATP has been shown to positively influence PGE2 and nitric oxide 
production in the cells [38, 281]. These markers are an important factor in the regulation of 
osteoblastic activity and bone formation, which indirectly implies that the modulation by 
PUFA of FSS induced osteocytes may have a positive impact on bone health. In a general 
term, these results presented a hypothesis that regular dietary supplementation of PUFA 
may modulate the osteocytic membrane and exercise increases the cellular osteocytic 
responses which collectively have a positive effect on bone health. 
There were some limitations to our experiment designs. It was not possible to collect the 
media in smaller time frames. It would be nice to see the ATP secretion pattern of MLO-Y4 
cells in the first few seconds at the start of the experiments. The closed circuit system of 
our equipment hindered our evaluation of the real time release of ATP by the MLO-Y4 cells. 
Cell viability assays after the end of each experiment could have presented us with more 
robust information about the obtained results as to whether any increase in ATP release 
reflects possible cell destruction in response to FSS. 
Further examinations of other molecules such as PGE2, NO in the collected medium may 
widen up our understanding and give a clear understanding about the mechanism behind 
ATP release and different pathways involved in osteocyte mechanosensation. Future work 
should focus on the effect of these PUFAs on different osteocytic markers such as RANKL, 
OPG, c-fos etc so that these loading and FA treatment studies could establish the osteocytic 
response in other signalling pathways. This work may lead to a novel mechanism of action 






1. Bonewald, L.F., The amazing osteocyte. J Bone Miner Res, 2011. 26(2): p. 229-38. 
2. Kruger, M.C., et al., Long-chain polyunsaturated fatty acids: selected mechanisms 
of action on bone. Prog Lipid Res, 2010. 49(4): p. 438-49. 
3. Kajarabille, N., et al., A new insight to bone turnover: role of omega-3 
polyunsaturated fatty acids. ScientificWorldJournal, 2013. 2013: p. 589641. 
4. Corwin, R.L., Effects of dietary fats on bone health in advanced age. Prostaglandins 
Leukot Essent Fatty Acids, 2003. 68(6): p. 379-86. 
5. Maggio, M., et al., The impact of omega-3 fatty acids on osteoporosis. Curr Pharm 
Des, 2009. 15(36): p. 4157-64. 
6. Stránský, M. and L. Rysava, Nutrition as prevention and treatment of osteoporosis. 
Physiol Res, 2009. 58(Suppl 1): p. S7-S11. 
7. Cheung, A.M. and L. Giangregorio, Mechanical stimuli and bone health: what is the 
evidence? Current opinion in rheumatology, 2012. 24(5): p. 561-566. 
8. Eleftheriou, K.I., et al., Bone structure and geometry in young men: the influence of 
smoking, alcohol intake and physical activity. Bone, 2013. 52(1): p. 17-26. 
9. Loprinzi, P.D., et al., Benefits and environmental determinants of physical activity in 
children and adolescents. Obesity Facts, 2012. 5(4): p. 597-610. 
10. Lee, Y.-S., et al., Relationships between physical activity and awareness and 
treatment status among adults with low femoral bone density in the United States. 
American Journal of Health Promotion, 2012. 27(1): p. 2-9. 
11. Gaillard, P., et al., Skeletal Tissue in Culture: Hormonal Regulation of Metabolism 
and Development. Clinical Orthopaedics and Related Research (1976-2007), 1979. 
142: p. 196-214. 
12. Mullur, R., Y.-Y. Liu, and G.A. Brent, Thyroid hormone regulation of metabolism. 
Physiological reviews, 2014. 94(2): p. 355-382. 
13. Hocquette, J., et al., Nutritional and hormonal regulation of energy metabolism in 
skeletal muscles of meat-producing animals. Livestock production science, 1998. 
56(2): p. 115-143. 
14. Bhathena, S.J., Relationship between fatty acids and the endocrine and 
neuroendocrine system. Nutr Neurosci, 2006. 9(1-2): p. 1-10. 
15. Soares, M., et al., Effect of essential fatty acid deficiency on membrane fatty acid 
content and growth hormone stimulation of rat pituitaries during postnatal 
development. Journal of lipid research, 1995. 36(6): p. 1401-1406. 
16. Castellano, C.-A., et al., Fish oil diets alter the phospholipid balance, fatty acid 
composition, and steroid hormone concentrations in testes of adult pigs. 
Theriogenology, 2011. 76(6): p. 1134-1145. 
17. Gibson, R.A., The effect of diets containing fish and fish oils on disease risk factors 




18. Iwamoto, J., [A role of exercise and sports in the prevention of osteoporosis.]. Clin 
Calcium, 2017. 27(1): p. 17-23. 
19. Russo, C.R., The effects of exercise on bone. Basic concepts and implications for the 
prevention of fractures. Clin Cases Miner Bone Metab, 2009. 6(3): p. 223-8. 
20. Leigey, D., et al., Participation in high-impact sports predicts bone mineral density 
in senior olympic athletes. Sports Health, 2009. 1(6): p. 508-13. 
21. Krum, S.A., Direct transcriptional targets of sex steroid hormones in bone. Journal 
of cellular biochemistry, 2011. 112(2): p. 401-408. 
22. Gardinier, J.D., F. Mohamed, and D.H. Kohn, PTH signaling during exercise 
contributes to bone adaptation. Journal of Bone and Mineral Research, 2015. 
30(6): p. 1053-1063. 
23. Sato, K., et al., Resistance training restores muscle sex steroid hormone 
steroidogenesis in older men. The FASEB Journal, 2014. 28(4): p. 1891-1897. 
24. Guerrini, M.M. and H. Takayanagi, The immune system, bone and RANKL. Archives 
of biochemistry and biophysics, 2014. 561: p. 118-123. 
25. Yoshiya, S., [The effects of exercise and sports activities on bone and joint 
morbidities.]. Clin Calcium, 2017. 27(1): p. 39-43. 
26. Klein-Nulend, J., et al., Sensitivity of osteocytes to biomechanical stress in vitro. The 
FASEB Journal, 1995. 9(5): p. 441-445. 
27. McAllister, T., T. Du, and J. Frangos, Fluid shear stress stimulates prostaglandin and 
nitric oxide release in bone marrow-derived preosteoclast-like cells. Biochemical 
and biophysical research communications, 2000. 270(2): p. 643-648. 
28. McGarry, J.G., J. Klein-Nulend, and P.J. Prendergast, The effect of cytoskeletal 
disruption on pulsatile fluid flow-induced nitric oxide and prostaglandin E2 release 
in osteocytes and osteoblasts. Biochemical and biophysical research 
communications, 2005. 330(1): p. 341-348. 
29. Chow, J.W., Role of nitric oxide and prostaglandins in the bone formation response 
to mechanical loading. Exerc Sport Sci Rev, 2000. 28(4): p. 185-8. 
30. Lean, J.M., et al., Osteocytic expression of mRNA for c-fos and IGF-I: an immediate 
early gene response to an osteogenic stimulus. Am J Physiol, 1996. 270(6 Pt 1): p. 
E937-45. 
31. Dallas, S.L., M. Prideaux, and L.F. Bonewald, The osteocyte: an endocrine cell ... and 
more. Endocr Rev, 2013. 34(5): p. 658-90. 
32. Fritton, S.P. and S. Weinbaum, Fluid and Solute Transport in Bone: Flow-Induced 
Mechanotransduction. Annu Rev Fluid Mech, 2009. 41: p. 347-374. 
33. Zaman, G., et al., Mechanical strain stimulates nitric oxide production by rapid 
activation of endothelial nitric oxide synthase in osteocytes. J Bone Miner Res, 
1999. 14(7): p. 1123-31. 





35. Immobilisation Osteoporosis, in Bisphosphonates in Medical Practice: Actions — 
Side Effects — Indications — Strategies, R. Bartl, et al., Editors. 2007, Springer 
Berlin Heidelberg: Berlin, Heidelberg. p. 111-113. 
36. Eimori, K., et al., Disrupted Bone Metabolism in Long-Term Bedridden Patients. 
PLoS One, 2016. 11(6): p. e0156991. 
37. Romanello, M., et al., Mechanically induced ATP release from human osteoblastic 
cells. Biochem Biophys Res Commun, 2001. 289(5): p. 1275-81. 
38. Genetos, D.C., et al., Fluid shear-induced ATP secretion mediates prostaglandin 
release in MC3T3-E1 osteoblasts. J Bone Miner Res, 2005. 20(1): p. 41-9. 
39. Grygorczyk, R. and J.W. Hanrahan, CFTR-independent ATP release from epithelial 
cells triggered by mechanical stimuli. Am J Physiol, 1997. 272(3 Pt 1): p. C1058-66. 
40. Lazarowski, E.R., et al., Direct demonstration of mechanically induced release of 
cellular UTP and its implication for uridine nucleotide receptor activation. J Biol 
Chem, 1997. 272(39): p. 24348-54. 
41. Weinbaum, S., S.C. Cowin, and Y. Zeng, A model for the excitation of osteocytes by 
mechanical loading-induced bone fluid shear stresses. J Biomech, 1994. 27(3): p. 
339-60. 
42. Cowin, S.C., L. Moss-Salentijn, and M.L. Moss, Candidates for the mechanosensory 
system in bone. J Biomech Eng, 1991. 113(2): p. 191-7. 
43. Kufahl, R.H. and S. Saha, A theoretical model for stress-generated fluid flow in the 
canaliculi-lacunae network in bone tissue. J Biomech, 1990. 23(2): p. 171-80. 
44. Riddle, R.C., et al., ATP Release Mediates Fluid Flow–Induced Proliferation of 
Human Bone Marrow Stromal Cells. Journal of Bone and Mineral Research, 2007. 
22(4): p. 589-600. 
45. Shimegi, S., ATP and adenosine act as a mitogen for osteoblast-like cells (MC3T3-
E1). Calcified Tissue International, 1996. 58(2): p. 109-113. 
46. Romanello, M., et al., Autocrine/paracrine stimulation of purinergic receptors in 
osteoblasts: contribution of vesicular ATP release. Biochemical and biophysical 
research communications, 2005. 331(4): p. 1429-1438. 
47. You, J., et al., P2Y purinoceptors are responsible for oscillatory fluid flow-induced 
intracellular calcium mobilization in osteoblastic cells. J Biol Chem, 2002. 277(50): 
p. 48724-9. 
48. Jorgensen, N.R., et al., ATP- and gap junction-dependent intercellular calcium 
signaling in osteoblastic cells. J Cell Biol, 1997. 139(2): p. 497-506. 
49. Costessi, A., et al., Extracellular nucleotides activate Runx2 in the osteoblast-like 
HOBIT cell line: a possible molecular link between mechanical stress and 
osteoblasts' response. Bone, 2005. 36(3): p. 418-32. 
50. Bowler, W.B., et al., Signaling in human osteoblasts by extracellular nucleotides. 
Their weak induction of the c-fos proto-oncogene via Ca2+ mobilization is strongly 




independently of mitogen-activated protein kinase. J Biol Chem, 1999. 274(20): p. 
14315-24. 
51. Nakamura, E., et al., ATP activates DNA synthesis by acting on P2X receptors in 
human osteoblast-like MG-63 cells. Am J Physiol Cell Physiol, 2000. 279(2): p. C510-
9. 
52. Seifert, M.F. and B.A. Watkins, Role of dietary lipid and antioxidants in bone 
metabolism. Nutrition research, 1997. 17(7): p. 1209-1228. 
53. Tai, E.K., X.B. Wang, and Z.Y. Chen, An update on adding docosahexaenoic acid 
(DHA) and arachidonic acid (AA) to baby formula. Food Funct, 2013. 4(12): p. 1767-
75. 
54. Tarlton, J.F., et al., Reduced bone breakage and increased bone strength in free 
range laying hens fed omega-3 polyunsaturated fatty acid supplemented diets. 
Bone, 2013. 52(2): p. 578-586. 
55. Weiler, H.A., Dietary Supplementation of Arachidonic Acid Is Associated with 
Higher Whole Body Weight and Bone Mineral Density in Growing Pigs. Pediatric 
Research, 2000. 47(5): p. 692-697. 
56. Le, H.D., et al., The essentiality of arachidonic acid and docosahexaenoic acid. 
Prostaglandins Leukot Essent Fatty Acids, 2009. 81(2-3): p. 165-70. 
57. Bao, C.L.M., et al., Advances in Bone Tissue Engineering. 2013. 
58. Taichman, R.S., Blood and bone: two tissues whose fates are intertwined to create 
the hematopoietic stem-cell niche. Blood, 2005. 105(7): p. 2631-9. 
59. DeLuca, H.F., The metabolism and functions of vitamin D. Adv Exp Med Biol, 1986. 
196: p. 361-75. 
60. Fukumoto, S. and T.J. Martin, Bone as an endocrine organ. Trends Endocrinol 
Metab, 2009. 20(5): p. 230-6. 
61. Le, B.Q., et al., The Components of Bone and What They Can Teach Us about 
Regeneration. Materials (Basel), 2017. 11(1). 
62. Kong, L., et al., Integrin‐associated molecules and signalling cross talking in 
osteoclast cytoskeleton regulation. Journal of Cellular and Molecular Medicine, 
2020. 
63. Boyce, B.F., Advances in osteoclast biology reveal potential new drug targets and 
new roles for osteoclasts. Journal of Bone and Mineral Research, 2013. 28(4): p. 
711-722. 
64. Edwards, J.C., et al., c-Src control of chloride channel support for osteoclast HCl 
transport and bone resorption. J Biol Chem, 2006. 281(38): p. 28011-22. 
65. Novack, D.V. and G. Mbalaviele, Osteoclasts—key players in skeletal health and 
disease. Myeloid Cells in Health and Disease: A Synthesis, 2017: p. 235-255. 
66. Carulli, C., M. Innocenti, and M.L. Brandi, Bone Vascularization in Normal and 




67. Palmer, R.M., A.G. Ferrige, and S. Moncada, Nitric oxide release accounts for the 
biological activity of endothelium-derived relaxing factor. Nature, 1987. 327(6122): 
p. 524-6. 
68. Currey, J.D., The many adaptations of bone. J Biomech, 2003. 36(10): p. 1487-95. 
69. Marotti, G., The structure of bone tissues and the cellular control of their 
deposition. Ital J Anat Embryol, 1996. 101(4): p. 25-79. 
70. Franz-Odendaal, T.A., B.K. Hall, and P.E. Witten, Buried alive: how osteoblasts 
become osteocytes. Dev Dyn, 2006. 235(1): p. 176-90. 
71. Baud, C.A., [Morphology and inframicroscopic structure of osteocytes]. Acta Anat 
(Basel), 1962. 51: p. 209-25. 
72. Wysolmerski, J.J., Osteocytic osteolysis: time for a second look? Bonekey Rep, 
2012. 1: p. 229. 
73. Karsdal, M.A., et al., Matrix metalloproteinase-dependent activation of latent 
transforming growth factor-β controls the conversion of osteoblasts into osteocytes 
by blocking osteoblast apoptosis. Journal of Biological Chemistry, 2002. 277(46): p. 
44061-44067. 
74. Everts, V., et al., The bone lining cell: its role in cleaning Howship's lacunae and 
initiating bone formation. Journal of Bone and Mineral Research, 2002. 17(1): p. 
77-90. 
75. Matsuo, K. and N. Irie, Osteoclast–osteoblast communication. Archives of 
biochemistry and biophysics, 2008. 473(2): p. 201-209. 
76. Bouhtiauy, I., D. Lajeunesse, and M.G. Brunette, The mechanism of parathyroid 
hormone action on calcium reabsorption by the distal tubule. Endocrinology, 1991. 
128(1): p. 251-8. 
77. Civitelli, R. and K. Ziambaras, Calcium and phosphate homeostasis: concerted 
interplay of new regulators. J Endocrinol Invest, 2011. 34(7 Suppl): p. 3-7. 
78. Rasmussen, H., et al., Hormonal control of skeletal and mineral homeostasis. Am J 
Med, 1974. 56(6): p. 751-8. 
79. Egbuna, O.I. and E.M. Brown, Hypercalcaemic and hypocalcaemic conditions due to 
calcium-sensing receptor mutations. Best Pract Res Clin Rheumatol, 2008. 22(1): p. 
129-48. 
80. Jono, S., et al., 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by 
modulating secretion of endogenous parathyroid hormone-related peptide. 
Circulation, 1998. 98(13): p. 1302-6. 
81. Cantley, L.K., et al., 1,25-Dihydroxyvitamin D3 suppresses parathyroid hormone 
secretion from bovine parathyroid cells in tissue culture. Endocrinology, 1985. 
117(5): p. 2114-9. 
82. Chan, Y.L., et al., The effect of 1,25 dihydroxycholecalciferol on parathyroid 
hormone secretion by monolayer cultures of bovine parathyroid cells. Calcif Tissue 




83. Lowik, C.W., et al., Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate 
interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in 
osteoclastogenesis. Biochem Biophys Res Commun, 1989. 162(3): p. 1546-52. 
84. Ishimi, Y., et al., IL-6 is produced by osteoblasts and induces bone resorption. J 
Immunol, 1990. 145(10): p. 3297-303. 
85. Hienz, S.A., S. Paliwal, and S. Ivanovski, Mechanisms of bone resorption in 
periodontitis. Journal of immunology research, 2015. 2015. 
86. Kudo, O., et al., Interleukin-6 and interleukin-11 support human osteoclast 
formation by a RANKL-independent mechanism. Bone, 2003. 32(1): p. 1-7. 
87. Fu, Q., et al., Parathyroid hormone stimulates receptor activator of NFkappa B 
ligand and inhibits osteoprotegerin expression via protein kinase A activation of 
cAMP-response element-binding protein. J Biol Chem, 2002. 277(50): p. 48868-75. 
88. Li, X., et al., Parathyroid hormone stimulates osteoblastic expression of MCP-1 to 
recruit and increase the fusion of pre/osteoclasts. J Biol Chem, 2007. 282(45): p. 
33098-106. 
89. Hoff, A.O., et al., Increased bone mass is an unexpected phenotype associated with 
deletion of the calcitonin gene. J Clin Invest, 2002. 110(12): p. 1849-57. 
90. Schinke, T., et al., Decreased bone formation and osteopenia in mice lacking alpha-
calcitonin gene-related peptide. J Bone Miner Res, 2004. 19(12): p. 2049-56. 
91. Huebner, A.K., et al., Calcitonin deficiency in mice progressively results in high bone 
turnover. J Bone Miner Res, 2006. 21(12): p. 1924-34. 
92. Tazawa, K., et al., Osteocytic osteolysis observed in rats to which parathyroid 
hormone was continuously administered. J Bone Miner Metab, 2004. 22(6): p. 524-
9. 
93. Baylink, D., E. Morey, and C. Rich, Effect of calcitonin on the rates of bone 
formation and resorption in the rat. Endocrinology, 1969. 84(2): p. 261-9. 
94. Clarke, M.V., et al., A Role for the Calcitonin Receptor to Limit Bone Loss During 
Lactation in Female Mice by Inhibiting Osteocytic Osteolysis. Endocrinology, 2015. 
156(9): p. 3203-14. 
95. Chen, Q., et al., Fate decision of mesenchymal stem cells: adipocytes or 
osteoblasts? Cell Death & Differentiation, 2016. 23(7): p. 1128-1139. 
96. Kramer, I., et al., Osteocyte Wnt/beta-catenin signaling is required for normal bone 
homeostasis. Mol Cell Biol, 2010. 30(12): p. 3071-85. 
97. Burgers, T.A. and B.O. Williams, Regulation of Wnt/beta-catenin signaling within 
and from osteocytes. Bone, 2013. 54(2): p. 244-9. 
98. Shoback, D., Update in osteoporosis and metabolic bone disorders. J Clin 
Endocrinol Metab, 2007. 92(3): p. 747-53. 
99. Shah, A.D., D. Shoback, and E.M. Lewiecki, Sclerostin inhibition: a novel therapeutic 





100. Korvala, J., et al., Mutations in LRP5 cause primary osteoporosis without features of 
OI by reducing Wnt signaling activity. BMC Medical Genetics, 2012. 13(1): p. 26. 
101. Norwitz, N.G., et al., LRP5, Bone Density, and Mechanical Stress: A Case Report and 
Literature Review. Frontiers in endocrinology, 2019. 10: p. 184-184. 
102. Balemans, W., et al., Identification of a 52 kb deletion downstream of the SOST 
gene in patients with van Buchem disease. Journal of medical genetics, 2002. 39(2): 
p. 91-97. 
103. Balemans, W., et al., A generalized skeletal hyperostosis in two siblings caused by a 
novel mutation in the SOST gene. Bone, 2005. 36(6): p. 943-947. 
104. Sebastian, A. and G.G. Loots, Genetics of Sost/SOST in sclerosteosis and van 
Buchem disease animal models. Metabolism, 2018. 80: p. 38-47. 
105. Burger, E.H. and J. Klein-Nulend, Mechanotransduction in bone--role of the lacuno-
canalicular network. FASEB J, 1999. 13 Suppl: p. S101-12. 
106. Andersen, T.L., et al., A physical mechanism for coupling bone resorption and 
formation in adult human bone. Am J Pathol, 2009. 174(1): p. 239-47. 
107. Mosley, J.R., Osteoporosis and bone functional adaptation: mechanobiological 
regulation of bone architecture in growing and adult bone, a review. J Rehabil Res 
Dev, 2000. 37(2): p. 189-99. 
108. Schaffler, M.B., et al., Osteocytes: master orchestrators of bone. Calcif Tissue Int, 
2014. 94(1): p. 5-24. 
109. Honma, M., et al., RANKL subcellular trafficking and regulatory mechanisms in 
osteocytes. J Bone Miner Res, 2013. 28(9): p. 1936-49. 
110. Nakashima, T., et al., Evidence for osteocyte regulation of bone homeostasis 
through RANKL expression. Nat Med, 2011. 17(10): p. 1231-4. 
111. Xiong, J., et al., Matrix-embedded cells control osteoclast formation. Nat Med, 
2011. 17(10): p. 1235-41. 
112. Pfeilschifter, J., S.M. Seyedin, and G.R. Mundy, Transforming growth factor beta 
inhibits bone resorption in fetal rat long bone cultures. J Clin Invest, 1988. 82(2): p. 
680-5. 
113. Heino, T.J., T.A. Hentunen, and H.K. Vaananen, Osteocytes inhibit osteoclastic bone 
resorption through transforming growth factor-beta: enhancement by estrogen. J 
Cell Biochem, 2002. 85(1): p. 185-97. 
114. Loveridge, N., et al., Patterns of osteocytic endothelial nitric oxide synthase 
expression in the femoral neck cortex: differences between cases of intracapsular 
hip fracture and controls. Bone, 2002. 30(6): p. 866-71. 
115. Bonewald, L.F. and G.R. Mundy, Role of transforming growth factor-beta in bone 
remodeling. Clin Orthop Relat Res, 1990(250): p. 261-76. 
116. Poole, K.E., et al., Sclerostin is a delayed secreted product of osteocytes that 




117. Suen, P.K. and L. Qin, Sclerostin, an emerging therapeutic target for treating 
osteoporosis and osteoporotic fracture: A general review. Journal of Orthopaedic 
Translation, 2015. 4. 
118. ten Dijke, P., et al., Osteocyte-derived sclerostin inhibits bone formation: its role in 
bone morphogenetic protein and Wnt signaling. J Bone Joint Surg Am, 2008. 90 
Suppl 1: p. 31-5. 
119. van Bezooijen, R.L., et al., Wnt but not BMP signaling is involved in the inhibitory 
action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res, 2007. 
22(1): p. 19-28. 
120. Tu, X., et al., Sost downregulation and local Wnt signaling are required for the 
osteogenic response to mechanical loading. Bone, 2012. 50(1): p. 209-17. 
121. Boyden, L.M., et al., High bone density due to a mutation in LDL-receptor-related 
protein 5. N Engl J Med, 2002. 346(20): p. 1513-21. 
122. Li, X., et al., Sclerostin antibody treatment increases bone formation, bone mass, 
and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner 
Res, 2009. 24(4): p. 578-88. 
123. Hirvonen, M.J., et al., Novel perspectives on the transcytotic route in osteoclasts. 
Bonekey Rep, 2013. 2: p. 306. 
124. Niedzwiedzki, T. and J. Filipowska, Bone remodeling in the context of cellular and 
systemic regulation: the role of osteocytes and the nervous system. J Mol 
Endocrinol, 2015. 55(2): p. R23-36. 
125. Torreggiani, E., et al., Preosteocytes/osteocytes have the potential to 
dedifferentiate becoming a source of osteoblasts. PLoS One, 2013. 8(9): p. e75204. 
126. Sawa, N., et al., Alternating Differentiation and Dedifferentiation between Mature 
Osteoblasts and Osteocytes. Scientific Reports, 2019. 9(1): p. 13842. 
127. Pereira, R.C., et al., Patterns of FGF-23, DMP1, and MEPE expression in patients 
with chronic kidney disease. Bone, 2009. 45(6): p. 1161-8. 
128. Karsenty, G. and E.F. Wagner, Reaching a genetic and molecular understanding of 
skeletal development. Dev Cell, 2002. 2(4): p. 389-406. 
129. Parfitt, A.M., Osteonal and hemi-osteonal remodeling: the spatial and temporal 
framework for signal traffic in adult human bone. J Cell Biochem, 1994. 55(3): p. 
273-86. 
130. Zhang, S., et al., Osteoclast regulation of osteoblasts via RANKRANKL reverse signal 
transduction in vitro. Mol Med Rep, 2017. 16(4): p. 3994-4000. 
131. Ottewell, P.D., The role of osteoblasts in bone metastasis. J Bone Oncol, 2016. 5(3): 
p. 124-127. 
132. Tresguerres, F.G.F., et al., The osteocyte: A multifunctional cell within the bone. 
Ann Anat, 2020. 227: p. 151422. 
133. Stransky, M. and L. Rysava, Nutrition as prevention and treatment of osteoporosis. 




134. Tveit, M., et al., Bone mass following physical activity in young years: a mean 39-
year prospective controlled study in men. Osteoporos Int, 2013. 24(4): p. 1389-97. 
135. Fernandes, G., R. Lawrence, and D. Sun, Protective role of n-3 lipids and soy protein 
in osteoporosis. Prostaglandins Leukot Essent Fatty Acids, 2003. 68(6): p. 361-72. 
136. Sun, D., et al., Dietary n-3 fatty acids decrease osteoclastogenesis and loss of bone 
mass in ovariectomized mice. J Bone Miner Res, 2003. 18(7): p. 1206-16. 
137. Zhang, J., et al., Feeding blueberry diets to young rats dose-dependently inhibits 
bone resorption through suppression of RANKL in stromal cells. PLoS One, 2013. 
8(8): p. e70438. 
138. Kontogianni, M.D., et al., Association between dietary patterns and indices of bone 
mass in a sample of Mediterranean women. Nutrition, 2009. 25(2): p. 165-71. 
139. Johnell, O., et al., The apparent incidence of hip fracture in Europe: a study of 
national register sources. Osteoporos Int, 1992. 2(6): p. 298-302. 
140. Bertoli, S., et al., [Nutritional status and bone mineral mass in children treated with 
ketogenic diet]. Recenti Prog Med, 2002. 93(12): p. 671-5. 
141. Orchard, T.S., et al., The association of red blood cell n‐3 and n‐6 fatty acids with 
bone mineral density and hip fracture risk in the women's health initiative. Journal 
of Bone and Mineral Research, 2013. 28(3): p. 505-515. 
142. Orchard, T.S., et al., A systematic review of omega-3 fatty acids and osteoporosis. 
Br J Nutr, 2012. 107 Suppl 2: p. S253-60. 
143. Lozupone, E., et al., Intermittent compressive load stimulates osteogenesis and 
improves osteocyte viability in bones cultured "in vitro". Clin Rheumatol, 1996. 
15(6): p. 563-72. 
144. Bakker, A., J. Klein-Nulend, and E. Burger, Shear stress inhibits while disuse 
promotes osteocyte apoptosis. Biochem Biophys Res Commun, 2004. 320(4): p. 
1163-8. 
145. Aguirre, J.I., et al., Osteocyte apoptosis is induced by weightlessness in mice and 
precedes osteoclast recruitment and bone loss. J Bone Miner Res, 2006. 21(4): p. 
605-15. 
146. Morse, L.R., et al., Severe Spinal Cord Injury Causes Immediate Multi-cellular 
Dysfunction at the Chondro-Osseous Junction. Transl Stroke Res, 2011. 2(4): p. 643-
50. 
147. Verborgt, O., G.J. Gibson, and M.B. Schaffler, Loss of osteocyte integrity in 
association with microdamage and bone remodeling after fatigue in vivo. J Bone 
Miner Res, 2000. 15(1): p. 60-7. 
148. Noble, B.S., et al., Mechanical loading: biphasic osteocyte survival and targeting of 
osteoclasts for bone destruction in rat cortical bone. Am J Physiol Cell Physiol, 
2003. 284(4): p. C934-43. 
149. Heino, T.J., et al., Evidence for the role of osteocytes in the initiation of targeted 




150. Cardoso, L., et al., Osteocyte apoptosis controls activation of intracortical 
resorption in response to bone fatigue. J Bone Miner Res, 2009. 24(4): p. 597-605. 
151. Tatsumi, S., et al., Targeted ablation of osteocytes induces osteoporosis with 
defective mechanotransduction. Cell Metab, 2007. 5(6): p. 464-75. 
152. Bikle, D.D. and B.P. Halloran, The response of bone to unloading. J Bone Miner 
Metab, 1999. 17(4): p. 233-44. 
153. Carmeliet, G., L. Vico, and R. Bouillon, Space flight: a challenge for normal bone 
homeostasis. Crit Rev Eukaryot Gene Expr, 2001. 11(1-3): p. 131-44. 
154. Bikle, D.D., T. Sakata, and B.P. Halloran, The impact of skeletal unloading on bone 
formation. Gravit Space Biol Bull, 2003. 16(2): p. 45-54. 
155. Smith, S.M., et al., Bone markers, calcium metabolism, and calcium kinetics during 
extended-duration space flight on the mir space station. J Bone Miner Res, 2005. 
20(2): p. 208-18. 
156. Adami, S., et al., Site-specific effects of strength training on bone structure and 
geometry of ultradistal radius in postmenopausal women. J Bone Miner Res, 1999. 
14(1): p. 120-4. 
157. Maddalozzo, G.F. and C.M. Snow, High intensity resistance training: effects on bone 
in older men and women. Calcif Tissue Int, 2000. 66(6): p. 399-404. 
158. Guadalupe-Grau, A., et al., Exercise and bone mass in adults. Sports Med, 2009. 
39(6): p. 439-68. 
159. Hamilton, C.J., V.J. Swan, and S.A. Jamal, The effects of exercise and physical 
activity participation on bone mass and geometry in postmenopausal women: a 
systematic review of pQCT studies. Osteoporos Int, 2010. 21(1): p. 11-23. 
160. Isaksson, H., et al., Physical exercise improves properties of bone and its collagen 
network in growing and maturing mice. Calcif Tissue Int, 2009. 85(3): p. 247-56. 
161. Main, R.P., M.E. Lynch, and M.C. van der Meulen, Load-induced changes in bone 
stiffness and cancellous and cortical bone mass following tibial compression 
diminish with age in female mice. J Exp Biol, 2014. 217(Pt 10): p. 1775-83. 
162. Gross, T.S., et al., Selected Contribution: Osteocytes upregulate HIF-1α in response 
to acute disuse and oxygen deprivation. Journal of Applied Physiology, 2001. 90(6): 
p. 2514-2519. 
163. Dodd, J.S., J.A. Raleigh, and T.S. Gross, Osteocyte hypoxia: a novel 
mechanotransduction pathway. Am J Physiol, 1999. 277(3): p. C598-602. 
164. Gross, T.S., et al., Upregulation of osteopontin by osteocytes deprived of 
mechanical loading or oxygen. J Bone Miner Res, 2005. 20(2): p. 250-6. 
165. Giachelli, C.M. and S. Steitz, Osteopontin: a versatile regulator of inflammation and 
biomineralization. Matrix Biol, 2000. 19(7): p. 615-22. 
166. Roesler, H., Some historical remarks on the theory of cancellous bone structure 
(Wolff's Law), in Mechanical Properties of Bone, S.C. Cowin, Editor. 1981: ASME, 




167. Skedros, J.G. and R.A. Brand, Biographical Sketch: Georg Hermann von Meyer 
(1815–1892). Clinical Orthopaedics and Related Research, 2011. 469(11): p. 3072-
3076. 
168. Wolff, J., The Law of Bone Remodelling. 1 ed. 1986: Springer-Verlag Berlin 
Heidelberg. 126. 
169. Skedros, J.G. and S.L. Baucom, Mathematical analysis of trabecular 'trajectories' in 
apparent trajectorial structures: the unfortunate historical emphasis on the human 
proximal femur. J Theor Biol, 2007. 244(1): p. 15-45. 
170. Skerrry, T.M., Models for mechanical loading of bone and bone cells in vivo and in 
vitro, in Methods in bone biology, T.R. Arnett and B. Henderson, Editors. 1998, 
Chapman & Hall: London. p. 149-176. 
171. Frost, H.M., Bone "mass" and the "mechanostat": a proposal. Anat Rec, 1987. 
219(1): p. 1-9. 
172. Robling, A.G., et al., Shorter, more frequent mechanical loading sessions enhance 
bone mass. Medicine & Science in Sports & Exercise, 2002. 34(2): p. 196-202. 
173. Lee, K.C. and L.E. Lanyon, Mechanical loading influences bone mass through 
estrogen receptor α. Exercise and sport sciences reviews, 2004. 32(2): p. 64-68. 
174. Zhang, P., K. Hamamura, and H. Yokota, A brief review of bone adaptation to 
unloading. Genomics, proteomics & bioinformatics, 2008. 6(1): p. 4-7. 
175. Alexandre, C. and L. Vico, Pathophysiology of bone loss in disuse osteoporosis. Joint 
Bone Spine, 2011. 78(6): p. 572-576. 
176. Atkins, G. and D. Findlay, Osteocyte regulation of bone mineral: a little give and 
take. Osteoporosis international, 2012. 23(8): p. 2067-2079. 
177. Bonewald, L.F., Mechanosensation and Transduction in Osteocytes. Bonekey 
Osteovision, 2006. 3(10): p. 7-15. 
178. Kamioka, H., T. Honjo, and T. Takano-Yamamoto, A three-dimensional distribution 
of osteocyte processes revealed by the combination of confocal laser scanning 
microscopy and differential interference contrast microscopy. Bone, 2001. 28(2): p. 
145-9. 
179. Ciani, C., S.B. Doty, and S.P. Fritton, Mapping bone interstitial fluid movement: 
displacement of ferritin tracer during histological processing. Bone, 2005. 37(3): p. 
379-87. 
180. Knothe Tate, M.L., "Whither flows the fluid in bone?" An osteocyte's perspective. J 
Biomech, 2003. 36(10): p. 1409-24. 
181. Knothe Tate, M.L., P. Niederer, and U. Knothe, In vivo tracer transport through the 
lacunocanalicular system of rat bone in an environment devoid of mechanical 
loading. Bone, 1998. 22(2): p. 107-17. 
182. Robling, A.G. and C.H. Turner, Mechanical signaling for bone modeling and 




183. Mi, L.Y., et al., Analysis of avian bone response to mechanical loading. Part two: 
Development of a computational connected cellular network to study bone 
intercellular communication. Biomech Model Mechanobiol, 2005. 4(2-3): p. 132-
46. 
184. Dallas, S.L. and L.F. Bonewald, Dynamics of the transition from osteoblast to 
osteocyte. Ann N Y Acad Sci, 2010. 1192: p. 437-43. 
185. Klein-Nulend, J., et al., Donor age and mechanosensitivity of human bone cells. 
Osteoporos Int, 2002. 13(2): p. 137-46. 
186. Nicolella, D.P., et al., Osteocyte lacunae tissue strain in cortical bone. J Biomech, 
2006. 39(9): p. 1735-43. 
187. Han, Y., et al., Mechanotransduction and strain amplification in osteocyte cell 
processes. Proc Natl Acad Sci U S A, 2004. 101(47): p. 16689-94. 
188. You, L.D., et al., Ultrastructure of the osteocyte process and its pericellular matrix. 
Anat Rec A Discov Mol Cell Evol Biol, 2004. 278(2): p. 505-13. 
189. Wang, Y., et al., A model for the role of integrins in flow induced 
mechanotransduction in osteocytes. Proc Natl Acad Sci U S A, 2007. 104(40): p. 
15941-6. 
190. Cherian, P.P., et al., Mechanical strain opens connexin 43 hemichannels in 
osteocytes: a novel mechanism for the release of prostaglandin. Molecular biology 
of the cell, 2005. 16(7): p. 3100-3106. 
191. Jiang, J.X. and P.P. Cherian, Hemichannels formed by connexin 43 play an 
important role in the release of prostaglandin E2by osteocytes in response to 
mechanical strain. Cell communication & adhesion, 2003. 10(4-6): p. 259-264. 
192. Riquelme, M.A., et al., Mitogen-activated protein kinase (MAPK) activated by 
prostaglandin E2 phosphorylates connexin 43 and closes osteocytic hemichannels 
in response to continuous flow shear stress. Journal of Biological Chemistry, 2015. 
290(47): p. 28321-28328. 
193. Pavalko, F.M., et al., A model for mechanotransduction in bone cells: the load-
bearing mechanosomes. J Cell Biochem, 2003. 88(1): p. 104-12. 
194. Geiger, B. and A. Bershadsky, Exploring the neighborhood: adhesion-coupled cell 
mechanosensors. Cell, 2002. 110(2): p. 139-42. 
195. Puklin-Faucher, E., et al., How the headpiece hinge angle is opened: New insights 
into the dynamics of integrin activation. J Cell Biol, 2006. 175(2): p. 349-60. 
196. Friedland, J.C., M.H. Lee, and D. Boettiger, Mechanically activated integrin switch 
controls alpha5beta1 function. Science, 2009. 323(5914): p. 642-4. 
197. Bonewald, L.F., Osteocytes as dynamic multifunctional cells. Ann N Y Acad Sci, 
2007. 1116: p. 281-90. 
198. Anderson, E.J., et al., Nano-microscale models of periosteocytic flow show 
differences in stresses imparted to cell body and processes. Ann Biomed Eng, 2005. 




199. Ainsworth, C., Cilia: tails of the unexpected. Nature, 2007. 448(7154): p. 638-41. 
200. Whitfield, J.F., How to grow bone to treat osteoporosis and mend fractures. Curr 
Osteoporos Rep, 2003. 1(1): p. 32-40. 
201. Schwartz, E.A., et al., Analysis and modeling of the primary cilium bending response 
to fluid shear. Am J Physiol, 1997. 272(1 Pt 2): p. F132-8. 
202. Malone, A.M., et al., Primary cilia mediate mechanosensing in bone cells by a 
calcium-independent mechanism. Proc Natl Acad Sci U S A, 2007. 104(33): p. 
13325-30. 
203. Xiao, Z., et al., Cilia-like structures and polycystin-1 in osteoblasts/osteocytes and 
associated abnormalities in skeletogenesis and Runx2 expression. J Biol Chem, 
2006. 281(41): p. 30884-95. 
204. Bakker, A.D., et al., The production of nitric oxide and prostaglandin E(2) by primary 
bone cells is shear stress dependent. J Biomech, 2001. 34(5): p. 671-7. 
205. Bacabac, R.G., et al., Nitric oxide production by bone cells is fluid shear stress rate 
dependent. Biochem Biophys Res Commun, 2004. 315(4): p. 823-9. 
206. Braunstein, G.M., et al., Cystic fibrosis transmembrane conductance regulator 
facilitates ATP release by stimulating a separate ATP release channel for autocrine 
control of cell volume regulation. J Biol Chem, 2001. 276(9): p. 6621-30. 
207. Sprague, R.S., et al., Deformation-induced ATP release from red blood cells requires 
CFTR activity. Am J Physiol, 1998. 275(5): p. H1726-32. 
208. Cotrina, M.L., et al., Connexins regulate calcium signaling by controlling ATP 
release. Proc Natl Acad Sci U S A, 1998. 95(26): p. 15735-40. 
209. Knight, G.E., et al., ATP is released from guinea pig ureter epithelium on distension. 
Am J Physiol Renal Physiol, 2002. 282(2): p. F281-8. 
210. Bodin, P. and G. Burnstock, Increased release of ATP from endothelial cells during 
acute inflammation. Inflamm Res, 1998. 47(8): p. 351-4. 
211. Wei, X.Q., et al., Altered immune responses in mice lacking inducible nitric oxide 
synthase. Nature, 1995. 375(6530): p. 408-11. 
212. Fox, S.W., T.J. Chambers, and J.W. Chow, Nitric oxide is an early mediator of the 
increase in bone formation by mechanical stimulation. Am J Physiol, 1996. 270(6 Pt 
1): p. E955-60. 
213. van't Hof, R.J. and S.H. Ralston, Nitric oxide and bone. Immunology, 2001. 103(3): 
p. 255-61. 
214. Moncada, S. and E.A. Higgs, The discovery of nitric oxide and its role in vascular 
biology. Br J Pharmacol, 2006. 147 Suppl 1: p. S193-201. 
215. Zhou, L. and D.Y. Zhu, Neuronal nitric oxide synthase: structure, subcellular 
localization, regulation, and clinical implications. Nitric Oxide, 2009. 20(4): p. 223-
30. 
216. Kato, Y., et al., Establishment of an osteocyte-like cell line, MLO-Y4. J Bone Miner 




217. Rosser, J. and L.F. Bonewald, Studying osteocyte function using the cell lines MLO-
Y4 and MLO-A5. Methods Mol Biol, 2012. 816: p. 67-81. 
218. Delgado-Calle, J., A.Y. Sato, and T. Bellido, Role and mechanism of action of 
sclerostin in bone. Bone, 2017. 96: p. 29-37. 
219. Bonewald, L.F. and M.L. Johnson, Osteocytes, mechanosensing and Wnt signaling. 
Bone, 2008. 42(4): p. 606-15. 
220. Brown, R., J. Jouli, and P. Samms, General Organic Chemistry, Vol. 8. 1985, Khimiya, 
Moscow. 
221. Salari, P., et al., A systematic review of the impact of n-3 fatty acids in bone health 
and osteoporosis. Med Sci Monit, 2008. 14(3): p. RA37-44. 
222. Mayes, P.A. and K.M. Botham, Metabolism of unsaturated fatty acids and 
eicosanoids. Harper’s Illustrated Biochemistry, 26th Ed.(Lange Medical Books, New 
York) p, 2003: p. 190-196. 
223. de Gomez Dumm, I.N. and R.R. Brenner, Oxidative desaturation of alpha-linoleic, 
linoleic, and stearic acids by human liver microsomes. Lipids, 1975. 10(6): p. 315-7. 
224. Emken, E., et al., Synthesis and applications of isotopically labelled compounds 
1988. 1989, Amsterdam: Elsevier Science Publishers. 
225. Claassen, N., et al., The effect of different n-6/n-3 essential fatty acid ratios on 
calcium balance and bone in rats. Prostaglandins Leukot Essent Fatty Acids, 1995. 
53(1): p. 13-9. 
226. Zarate, R., et al., Significance of long chain polyunsaturated fatty acids in human 
health. Clin Transl Med, 2017. 6(1): p. 25. 
227. Fekete, K. and T. Decsi, Long-chain polyunsaturated fatty acids in inborn errors of 
metabolism. Nutrients, 2010. 2(9): p. 965-74. 
228. Griel, A.E., et al., An increase in dietary n-3 fatty acids decreases a marker of bone 
resorption in humans. Nutrition Journal, 2007. 6(1): p. 2. 
229. Nawata, K., et al., Association of n-3 polyunsaturated fatty acid intake with bone 
mineral density in postmenopausal women. Calcified tissue international, 2013. 
93(2): p. 147-154. 
230. Kettler, D.B., Can manipulation of the ratios of essential fatty acids slow the rapid 
rate of postmenopausal bone loss? Alternative Medicine Review, 2001. 6(1): p. 61-
61. 
231. Brownbill, R.A., M. Petrosian, and J.Z. Ilich, Association between dietary conjugated 
linoleic acid and bone mineral density in postmenopausal women. Journal of the 
american college of nutrition, 2005. 24(3): p. 177-181. 
232. Fonolla-Joya, J., et al., Daily intake of milk enriched with n-3 fatty acids, oleic acid, 
and calcium improves metabolic and bone biomarkers in postmenopausal women. 




233. Kruger, M., et al., Calcium, gamma-linolenic acid and eicosapentaenoic acid 
supplementation in senile osteoporosis. Aging Clinical and Experimental Research, 
1998. 10(5): p. 385-394. 
234. Al-Nouri, D., A. Al-Khalifa, and F. Shahidi, Long-term supplementation of dietary 
omega-6/omega-3 ratios alters bone marrow fatty acid and biomarkers of bone 
metabolism in growing rabbits. Journal of Functional Foods, 2012. 4(3): p. 584-593. 
235. Watkins, B.A., et al., Dietary ratio of (n-6)/(n-3) polyunsaturated fatty acids alters 
the fatty acid composition of bone compartments and biomarkers of bone 
formation in rats. J Nutr, 2000. 130(9): p. 2274-84. 
236. Weiss, L.A., E. Barrett-Connor, and D. von Mühlen, Ratio of n–6 to n–3 fatty acids 
and bone mineral density in older adults: the Rancho Bernardo Study. The 
American Journal of Clinical Nutrition, 2005. 81(4): p. 934-938. 
237. Casado-Diaz, A., et al., The omega-6 arachidonic fatty acid, but not the omega-3 
fatty acids, inhibits osteoblastogenesis and induces adipogenesis of human 
mesenchymal stem cells: potential implication in osteoporosis. Osteoporosis 
International, 2013. 24(5): p. 1647-1661. 
238. Nagy, K. and I.-D. Tiuca, Importance of fatty acids in physiopathology of human 
body, in Fatty acids. 2017, IntechOpen. 
239. Koike, T., et al., Decreased membrane fluidity and unsaturated fatty acids in 
Niemann–Pick disease type C fibroblasts. Biochimica et Biophysica Acta (BBA) - 
Molecular Basis of Disease, 1998. 1406(3): p. 327-335. 
240. Maqbool, A., et al., Serum linoleic acid status as a clinical indicator of essential 
fatty acid status in children with cystic fibrosis. J Pediatr Gastroenterol Nutr, 2008. 
47(5): p. 635-44. 
241. Yao, J., et al., Dietary n3 polyunsaturated fatty acids ameliorate Crohn's disease in 
rats by modulating the expression of PPARgamma/NFAT. Mol Med Rep, 2017. 
16(6): p. 8315-8322. 
242. Gehrig, K.A. and J.G. Dinulos, Acrodermatitis due to nutritional deficiency. Curr 
Opin Pediatr, 2010. 22(1): p. 107-12. 
243. Aragona, P., et al., Systemic omega-6 essential fatty acid treatment and pge1 tear 
content in Sjogren's syndrome patients. Invest Ophthalmol Vis Sci, 2005. 46(12): p. 
4474-9. 
244. Rose, D.P. and M.A. Hatala, Dietary fatty acids and breast cancer invasion and 
metastasis. Nutrition and cancer, 1994. 21(2): p. 103-111. 
245. De, C.V., Effects of dietary fatty acid composition on tumor growth and metastasis. 
Anticancer research, 1992. 12(5): p. 1513-1522. 
246. Rose, D.P. and J.M. Connolly, Regulation of tumor angiogenesis by dietary fatty 
acids and eicosanoids. Nutrition and cancer, 2000. 37(2): p. 119-127. 
247. Maurin, A.C., et al., Role of polyunsaturated fatty acids in the inhibitory effect of 




248. Maurin, A.C., P.M. Chavassieux, and P.J. Meunier, Expression of PPARgamma and 
beta/delta in human primary osteoblastic cells: influence of polyunsaturated fatty 
acids. Calcif Tissue Int, 2005. 76(5): p. 385-92. 
249. Coetzee, M., et al., Effects of arachidonic acid, docosahexaenoic acid and 
prostaglandin E(2) on cell proliferation and morphology of MG-63 and MC3T3-E1 
osteoblast-like cells. Prostaglandins Leukot Essent Fatty Acids, 2007. 76(1): p. 35-
45. 
250. Song, J., et al., alpha-Linolenic Acid Inhibits Receptor Activator of NF-kappaB Ligand 
Induced (RANKL-Induced) Osteoclastogenesis and Prevents Inflammatory Bone Loss 
via Downregulation of Nuclear Factor-KappaB-Inducible Nitric Oxide Synthases (NF-
kappaB-iNOS) Signaling Pathways. Med Sci Monit, 2017. 23: p. 5056-5069. 
251. Babcock, T.A., et al., Omega-3 fatty acid lipid emulsion reduces LPS-stimulated 
macrophage TNF-α production. Surgical infections, 2002. 3(2): p. 145-149. 
252. Mishra, A., A. Chaudhary, and S. Sethi, Oxidized omega-3 fatty acids inhibit NF-κB 
activation via a PPARα-dependent pathway. Arteriosclerosis, thrombosis, and 
vascular biology, 2004. 24(9): p. 1621-1627. 
253. Innes, J.K. and P.C. Calder, Omega-6 fatty acids and inflammation. Prostaglandins, 
Leukotrienes and Essential Fatty Acids, 2018. 132: p. 41-48. 
254. Nakanishi, A., N. Iitsuka, and I. Tsukamoto, Fish oil suppresses bone resorption by 
inhibiting osteoclastogenesis through decreased expression of M-CSF, PU.1, MITF 
and RANK in ovariectomized rats. Mol Med Rep, 2013. 7(6): p. 1896-903. 
255. Boeyens, J.C., et al., Effects of omega3- and omega6-polyunsaturated fatty acids 
on RANKL-induced osteoclast differentiation of RAW264.7 cells: a comparative in 
vitro study. Nutrients, 2014. 6(7): p. 2584-601. 
256. Kasonga, A.E., et al., Arachidonic acid and docosahexaenoic acid suppress 
osteoclast formation and activity in human CD14+ monocytes, in vitro. PLoS One, 
2015. 10(4): p. e0125145. 
257. Casado-Diaz, A., et al., Effects of arachidonic acid on the concentration of 
hydroxyeicosatetraenoic acids in culture media of mesenchymal stromal cells 
differentiating into adipocytes or osteoblasts. Genes Nutr, 2014. 9(1): p. 375. 
258. Ostrom, R.S., C. Gregorian, and P.A. Insel, Cellular release of and response to ATP 
as key determinants of the set-point of signal transduction pathways. J Biol Chem, 
2000. 275(16): p. 11735-9. 
259. Lowry, O.H., et al., Protein measurement with the Folin phenol reagent. Journal of 
biological chemistry, 1951. 193: p. 265-275. 
260. Peterson, G.L., Review of the Folin phenol protein quantitation method of Lowry, 
Rosebrough, Farr and Randall. Analytical biochemistry, 1979. 100(2): p. 201-220. 
261. Maupin, K.A., et al., Skeletal adaptations in young male mice after 4 weeks aboard 




262. Coulombe, J.C., B. Senwar, and V.L. Ferguson, Spaceflight-Induced Bone Tissue 
Changes that Affect Bone Quality and Increase Fracture Risk. Curr Osteoporos Rep, 
2020. 
263. Mangano, K.M., et al., Polyunsaturated fatty acids and their relation with bone and 
muscle health in adults. Curr Osteoporos Rep, 2013. 11(3): p. 203-12. 
264. Berthiaume, F. and J.A. Frangos, Fluid flow increases membrane permeability to 
merocyanine 540 in human endothelial cells. Biochim Biophys Acta, 1994. 1191(1): 
p. 209-18. 
265. Murphy, M.G., Dietary fatty acids and membrane protein function. The Journal of 
nutritional biochemistry, 1990. 1(2): p. 68-79. 
266. Salem, J.N., et al., Specialization in membrane structure and metabolism with 
respect to polyunsaturated lipids. Progress in clinical and biological research, 1988. 
282: p. 319-333. 
267. Hishikawa, D., et al., Metabolism and functions of docosahexaenoic acid-containing 
membrane glycerophospholipids. FEBS Lett, 2017. 591(18): p. 2730-2744. 
268. Chabanel, A., et al., Influence of cholesterol content on red cell membrane 
viscoelasticity and fluidity. Biophys J, 1983. 44(2): p. 171-6. 
269. Coderch, L., et al., Influence of cholesterol on liposome fluidity by EPR. Relationship 
with percutaneous absorption. J Control Release, 2000. 68(1): p. 85-95. 
270. Alam, S.Q., A. Banerji, and B.S. Alam, Membrane fluidity and adenylate cyclase 
activity in the lacrimal glands of rats fed diets containing trans fatty acids. Curr Eye 
Res, 1985. 4(12): p. 1253-62. 
271. Cooper, R., et al., Modification of red cell membrane structure by cholesterol-rich 
lipid dispersions. A model for the primary spur cell defect. The Journal of clinical 
investigation, 1975. 55(1): p. 115-126. 
272. Cooper, R.A., Influence of increased membrane cholesterol on membrane fluidity 
and cell function in human red blood cells. Journal of supramolecular structure, 
1978. 8(4): p. 413-430. 
273. Cooper, R.A., J.R. Durocher, and M.H. Leslie, Decreased fluidity of red cell 
membrane lipids in abetalipoproteinemia. The Journal of clinical investigation, 
1977. 60(1): p. 115-121. 
274. Borochov, H., et al., The effect of phosphatidylcholine to sphingomyelin mole ratio 
on the dynamic properties of sheep erythrocyte membrane. Biochimica et 
Biophysica Acta (BBA)-Biomembranes, 1977. 470(3): p. 382-388. 
275. Genetos, D.C., et al., Oscillating fluid flow activation of gap junction hemichannels 
induces ATP release from MLO-Y4 osteocytes. J Cell Physiol, 2007. 212(1): p. 207-
14. 
276. Sutherland, E., et al., Biochemical localization of hepatic surface-membrane Na+, 
K+-ATPase activity depends on membrane lipid fluidity. Proceedings of the National 




277. Cooke, D.T. and R.S. Burden, Lipid modulation of plasma membrane‐bound 
ATPases. Physiologia Plantarum, 1990. 78(1): p. 153-159. 
278. Cheng, B., et al., Expression of functional gap junctions and regulation by fluid flow 
in osteocyte-like MLO-Y4 cells. J Bone Miner Res, 2001. 16(2): p. 249-59. 
279. Loiselle, A.E., J.X. Jiang, and H.J. Donahue, Gap junction and hemichannel functions 
in osteocytes. Bone, 2013. 54(2): p. 205-12. 
280. Wang, X., et al., Fluid Shear Stress Increases Osteocyte and Inhibits Osteoclasts via 
Downregulating Receptor-Activator of Nuclear Factor kappaB 
(RANK)/Osteoprotegerin Expression in Myeloma Microenvironment. Med Sci 
Monit, 2019. 25: p. 5961-5968. 
281. Andrews, A.M., et al., Shear stress-induced NO production is dependent on ATP 
autocrine signaling and capacitative calcium entry. Cellular and molecular 
bioengineering, 2014. 7(4): p. 510-520. 
 
 
